



**Commonwealth of Pennsylvania
Department of Human Services
Office of Medical Assistance Programs**

**2021 External Quality Review Report
United Healthcare**

Final Report
April 2022



Better healthcare,
realized.

Corporate Headquarters
1979 Marcus Avenue
Lake Success, NY 11042-1072
(516) 326-7767
ipro.org

ISO
9001:2015
CERTIFIED

Table of Contents

INTRODUCTION	4
PURPOSE AND BACKGROUND	4
I: VALIDATION OF PERFORMANCE IMPROVEMENT PROJECTS	6
OBJECTIVES	6
TECHNICAL METHODS OF DATA COLLECTION AND ANALYSIS	8
FINDINGS	9
II: PERFORMANCE MEASURES AND CAHPS SURVEY	13
OBJECTIVES	13
PA-SPECIFIC AND CMS CORE SET PERFORMANCE MEASURE SELECTION AND DESCRIPTIONS	19
HEDIS PERFORMANCE MEASURE SELECTION AND DESCRIPTIONS	22
IMPLEMENTATION OF PA-SPECIFIC PERFORMANCE MEASURES AND HEDIS AUDIT	27
CONCLUSIONS AND COMPARATIVE FINDINGS	27
CONSUMER ASSESSMENT OF HEALTHCARE PROVIDERS AND SYSTEMS (CAHPS) SURVEY	54
III: REVIEW OF COMPLIANCE WITH MEDICAID AND CHIP MANAGED CARE REGULATIONS	55
OBJECTIVES	55
DESCRIPTION OF DATA OBTAINED.....	55
DETERMINATION OF COMPLIANCE	57
FORMAT	57
FINDINGS	58
ACCREDITATION STATUS	61
IV: MCO RESPONSES TO THE PREVIOUS EQR RECOMMENDATIONS	62
CURRENT AND PROPOSED INTERVENTIONS	62
ROOT CAUSE ANALYSIS AND ACTION PLAN	62
UHC RESPONSE TO PREVIOUS EQR RECOMMENDATIONS	63
V: MCO STRENGTHS AND OPPORTUNITIES FOR IMPROVEMENT AND EQR RECOMMENDATIONS	66
STRENGTHS	66
OPPORTUNITIES FOR IMPROVEMENT	66
P4P MEASURE MATRIX REPORT CARD 2021 (MY 2020)	68
VI: SUMMARY OF ACTIVITIES	73
PERFORMANCE IMPROVEMENT PROJECTS.....	73
PERFORMANCE MEASURES.....	73
STRUCTURE AND OPERATIONS STANDARDS.....	73
2020 OPPORTUNITIES FOR IMPROVEMENT MCO RESPONSE.....	73
2021 STRENGTHS AND OPPORTUNITIES FOR IMPROVEMENT.....	73
APPENDIX	74
PERFORMANCE IMPROVEMENT PROJECT INTERVENTIONS	74

List of Tables and Figures

Table 1.1: Element Designation	9
Table 1.2: UHC PIP Compliance Assessments	12
Table 2.1: Performance Measure Groupings	13
Table 2.2: Access to/Availability of Care	30
Table 2.3: Well-Care Visits and Immunizations	31
Table 2.4: EPSDT: Screenings and Follow-up	34
Table 2.5: EPSDT: Dental Care for Children and Adults	36
Table 2.6: Women’s Health.....	37
Table 2.7: Obstetric and Neonatal Care.....	39
Table 2.8: Respiratory Conditions	42
Table 2.9: Comprehensive Diabetes Care	44
Table 2.10: Cardiovascular Care.....	46
Table 2.11: Utilization	49
Table 2.12: Utilization (Continued)	53
Table 2.13: CAHPS MY 2020 Adult Survey Results.....	54
Table 2.14: CAHPS MY 2020 Child Survey Results	54
Table 3.1: SMART Items Count per Regulation.....	56
Table 3.2: UHC Compliance with Enrollee Rights and Protections Regulations	58
Table 3.3: UHC Compliance with MCO, PIHP and PAHP Standards Regulations	59
Table 3.4: UHC Compliance with Quality Measurement and Improvement; External Quality Review Regulations	60
Table 3.5: UHC Compliance with Grievance and Appeal System Regulations.....	60
Table 4.1: UHC Response to Previous EQR Recommendations	63
Figure 5.1: P4P Measure Matrix – Rate Measures.....	70
Figure 5.2: P4P Measure Matrix – PCR Ratio Measure.....	70
Table 5.1: P4P Measure Rates.....	71
Table 5.2: EQR Recommendations.....	72
Table A.1.1: PIP Interventions.....	74

Healthcare Effectiveness Data and Information Set (HEDIS®) is a registered trademark of the National Committee for Quality Assurance (NCQA). NCQA™ is a trademark of the National Committee for Quality Assurance. Consumer Assessment of Healthcare Providers and Systems (CAHPS®) is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ).

Introduction

Purpose and Background

The final rule of the Balanced Budget Act (BBA) of 1997 requires that State agencies contract with an External Quality Review Organization (EQRO) to conduct an annual external quality review (EQR) of the services provided by contracted Medicaid Managed Care Organizations (MCOs). This EQR must include an analysis and evaluation of aggregated information on quality, timeliness and access to the health care services that a MCO furnishes to Medicaid Managed Care recipients. The Centers for Medicare & Medicaid Services (CMS) is required to develop EQR protocols to guide and support the annual EQR process. The first set of protocols was issued in 2003 and updated in 2012. CMS revised the protocols in 2018 to incorporate regulatory changes contained in the May 2016 Medicaid and CHIP managed care final rule. Updated protocols were published in late 2019.

The Commonwealth of Pennsylvania (PA) Department of Human Services (DHS) Office of Medical Assistance Programs (OMAP) contracted with IPRO as its EQRO to conduct the 2021 EQRs (Review Period: 1/1/2020 – 12/31/2020) for the HealthChoices PH MCOs and to prepare the technical reports. HealthChoices Physical Health (PH) is the mandatory managed care program that provides Medical Assistance (MA) recipients with physical health services in PA.

The mandatory EQR-related activities that must be included in detailed technical reports, per 42 C.F.R. §438.358, are as follows:

- validation of performance improvement projects,
- validation of MCO performance measures, and
- review of compliance with Medicaid and CHIP managed care regulations.

It should be noted that a fourth mandatory activity, validation of network adequacy, was named in the CMS *External Quality Review (EQR) Protocols* published in October 2019. However, CMS has not published an official protocol for this activity, and this activity is conducted at the state's discretion. Each managed care program agreement entered into by DHS identifies network adequacy standards for those programs. For PH MCOs, DHS has published multiple provider network standards through its Exhibit AAA: Provider Network Composition/Service Access; MCOs submit annual geographic access reports as outlined in these standards. DHS uses a web-based program to assist with ongoing network compliance and during the review year, its monitoring team planned implementation of new methods of verification, such as Access to Care campaigns, network spot checks, and provider directory reviews.

This technical report includes six core sections:

- I. Performance Improvement Projects
- II. Performance Measures and Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Survey
- III. Structure and Operation Standards
- IV. 2020 Opportunities for Improvement – MCO Response
- V. 2021 Strengths and Opportunities for Improvement
- VI. Summary of Activities

Information for **Section I** of this report is derived from activities conducted with and on behalf of DHS to research, select, and define Performance Improvement Projects (PIPs) for a new validation cycle, as well as IPRO's validation of each PH MCO's PIPs, including review of the PIP design and implementation using documents provided by the MCO.

Information for **Section II** of this report is derived from IPRO's validation of each PH MCO's performance measure submissions. Performance measure validation as conducted by IPRO includes PA-specific performance measures as well as Healthcare Effectiveness Data and Information Set (HEDIS®) measures for each Medicaid PH MCO. Within Section II, CAHPS Survey results follow the performance measures.

For the PH Medicaid MCOs, the information for the compliance with Structure and Operations Standards in **Section III** of the report is derived from the commonwealth's monitoring of the MCOs against the Systematic Monitoring, Access and

Retrieval Technology (SMART) standards, from the HealthChoices Agreement, and from National Committee for Quality Assurance (NCQA™) accreditation results for each MCO. This section also contains discussion of the revisions to the required structure and compliance standards presented in the updated EQR protocols.

Section IV, 2020 Opportunities for Improvement – MCO Response, includes the MCO’s responses to the 2020 EQR Technical Report’s opportunities for improvement and presents the degree to which the MCO addressed each opportunity for improvement.

Section V has a summary of the MCO’s strengths and opportunities for improvement for this review period as determined by IPRO and a “report card” of the MCO’s performance as related to selected HEDIS measures. **Section VI** provides a summary of EQR activities for the PH MCO for this review period.

I: Validation of Performance Improvement Projects

Objectives

Title 42 CFR § 438.330(d) establishes that state agencies require contracted MCO/MCPs to conduct PIPs that focus on both clinical and non-clinical areas. According to the CMS, the purpose of a PIP is to assess and improve the processes and outcomes of health care provided by an MCO/MCP.

In accordance with current BBA regulations, IPRO undertook validation of Performance Improvement Projects (PIPs) for each Medicaid PH MCO. For the purposes of the EQR, PH MCOs were required to participate in studies selected by OMAP for validation by IPRO in 2020 for 2019 activities. Under the applicable HealthChoices Agreement with the DHS in effect during this review period, Medicaid PH MCOs are required to conduct focused studies each year. For all PH MCOs, two PIPs were initiated as part of this requirement in 2020. For all PIPs, PH MCOs are required to implement improvement actions and to conduct follow-up in order to demonstrate initial and sustained improvement or the need for further action.

As part of the EQR PIP cycle that was initiated for all PH MCOs in 2020, PH MCOs were required to implement two internal PIPs in priority topic areas chosen by DHS. For this PIP cycle, two topics were selected: “Preventing Inappropriate Use or Overuse of Opioids” and “Reducing Potentially Preventable Hospital Admissions and Readmissions and Emergency Department Visits”.

“Preventing Inappropriate Use or Overuse of Opioids” was selected in light of the growing epidemic of accidental drug overdose in the United States, which is currently the leading cause of death in those under 50 years old living in the United States. In light of this, governmental regulatory agencies have released multiple regulatory measures and societal recommendations in an effort to decrease the amount of opioid prescriptions. PA DHS has sought to implement these measures as quickly as possible to impact its at-risk populations. While these measures are new and there is currently little historical data on these measures as of 2020, it remains a priority that future trends are monitored. MCOs were encouraged to develop aim statements, or objectives, for this project that look at preventing overuse/overdose, promoting treatment options, and stigma-reducing initiatives. Since the HEDIS Risk of Continued Opioid Use (COU) and CMS Adult Core Set Concurrent Use of Opioids and Benzodiazepines (COB) measures were first-year measures in 2019, a comparison to the national average was not available at project implementation. However, in PA, Use of Opioids at High Dosage (HDO) was found to be better than the national average for 2019, while Use of Opioids from Multiple Providers (UOP) was worse. The HEDIS UOP measure was worse than the national average for all three indicators: four or more prescribers, four or more pharmacies, and four or more prescribers and pharmacies.

In addition to increased collection of national measures, DHS has implemented mechanisms to examine other issues related to opioid use disorder (OUD) and coordinated treatment. In 2016, the governor of PA implemented the Centers of Excellence (COE) for Opioid Use Disorder program. Prior to COE implementation, 48% of Medicaid enrollees received OUD treatment, whereas after one year of implementation, 71% received treatment. Additionally, the DHS Quality Care Hospital Assessment Initiative, which focuses on ensuring access to quality hospital services for Pennsylvania Medical Assistance (MA) beneficiaries, was reauthorized in 2018 and included the addition of an Opioid Use Disorder (OUD) incentive. The incentive, based on follow up within 7 days for opioid treatment after a visit to the emergency department (ED) for opioid use disorder, allows hospitals the opportunity to earn incentives by implementing defined clinical pathways to help them get more individuals with OUD into treatment. The DHS also worked with the University of Pittsburgh to analyze OUD treatment, particularly MAT, for PA Medicaid enrollees. Among the findings presented in January 2020 were that the number of Medicaid enrollees receiving medication for OUD more than doubled from 2014-2018, and that the increase was driven by office-based prescriptions for buprenorphine or naltrexone, was seen for nearly all demographic sub-groups, and was higher for rural areas. Similarly, under the Drug and Treatment Act (DATA), prescription rates for buprenorphine have increased. This act allows qualifying practitioners to prescribe buprenorphine for OUD treatment from 30 up to 275 patients and is another component of DHS’ continuum of care.

Because opioid misuse and abuse is a national crisis, and due to the impact this has had particularly on PA, the new PH PIP is centered on opioids in the following four common outcome objectives: opioid prevention, harm reduction,

coordination/facilitation into treatment, and increase medicated-assisted treatment (MAT) utilization. For this PIP, the four outcome measures discussed above will be collected and in consideration of the initiatives already implemented in PA, three process oriented measures related to these initiatives will also be collected, focusing on the percentage of individuals with OUD who get into MAT, the duration of treatment for those that get into MAT, and follow-up after an emergency department (ED) visit for OUD. MCOs will define these three measures for their PIPs.

For this PIP, OMAP has required all PH MCOs to submit the following measures on an annual basis:

- Use of Opioids at High Dosage (HDO – HEDIS)
- Use of Opioids from Multiple Providers (UOP – HEDIS)
- Risk of Continued Opioid Use (COU – HEDIS)
- Concurrent Use of Opioids and Benzodiazepines (COB – CMS Adult Core Set)
- Percent of Individuals with OUD who receive MAT (MCO-defined)
- Percentage of adults > 18 years with pharmacotherapy for OUD who have (MCO-defined):
 - at least 90 and;
 - 180 days of continuous treatment
- Follow-up treatment within 7 days after ED visit for Opioid Use Disorder (MCO-defined)

Additionally, MCOs are expected to expand efforts to address health disparities in their populations. MCOs were instructed to identify race and ethnicity barriers and identify interventions that will be implemented to remediate the barriers identified.

“Reducing Potentially Preventable Hospital Admissions and Readmissions and Emergency Department Visits” was selected again due to several factors. General findings and recommendations from the PA Rethinking Care Program (RCP) – Serious Mental Illness (SMI) Innovation Project (RCP-SMI) and Joint PH/BH Readmission projects, as well as overall statewide readmission rates and results from several applicable HEDIS and PA Performance Measures across multiple years have highlighted this topic as an area of concern to be addressed for improvement. For the recently completed Readmissions PIP, several performance measures targeted at examining preventable hospitalizations and ED visits were collected, including measures collected as part of the PH-MCO and BH-MCO Integrated Care Plan (ICP) Program Pay for Performance Program, which was implemented in 2016 to address the needs of individuals with serious persistent mental illness (SPMI). From PIP reporting years 2016 to 2019, results were varied across measures and MCOs. Additionally, from 2017 to 2019, the ICP performance measures targeting the SPMI population showed inconsistent trends and little to no improvement in reducing hospitalizations and ED visits.

Research continues to indicate multiple factors that can contribute to preventable admissions and readmissions as well as the link between readmissions and mental illness. Additionally, within PA, there are existing initiatives that lend themselves to integration of care and targeting preventable hospitalizations, and can potentially be leveraged for applicable interventions. The Patient-Centered Medical Home (PCMH) model of patient care, which focuses on the whole person, taking both the individual’s PH and BH into account, has been added to the HealthChoices Agreement. The DHS Quality Care Hospital Assessment Initiative focuses on ensuring access to quality hospital services for PA MA beneficiaries. Under this initiative, the Hospital Quality Incentive Program (HQIP) builds off of existing DHS programs: MCO P4P, Provider P4P within HealthChoices PH, and the ICP Program. It focuses on preventable admissions and provides incentives for annual improvement or against a state benchmark.

Given the PA DHS initiatives that focus on coordination and integration of services and the inconsistent improvement on several metrics, it has become apparent that continued intervention in this area of healthcare for the HealthChoices population is warranted. MCOs were encouraged to develop aim statements for this project that look at reducing potentially avoidable ED visits and hospitalizations, including admissions that are avoidable initial admissions and readmissions that are potentially preventable.

For this PIP, OMAP has required all PH MCOs to submit the following core measures on an annual basis:

- Ambulatory Care (AMB): ED Utilization (HEDIS)
- Inpatient Utilization—General Hospital/Acute Care (IPU): Total Discharges (HEDIS)

- Plan All-Cause Readmissions (PCR – HEDIS)
- PH MCOs were given the criteria used to define the SPMI population, and will be collecting each of the following ICP measures using data from their own systems:
 - Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (MCO Defined)
 - Emergency Room Utilization for Individuals with SPMI (MCO Defined)
 - Inpatient Admission Utilization for Individuals with SPMI (MCO Defined)
 - Adherence to Antipsychotic Medications for Individual with Schizophrenia (MCO Defined)
 - Inpatient 30-Day Readmission Rate for Individuals with SPMI (MCO Defined)

Additionally, MCOs are expected to expand efforts to address health disparities in their populations. MCOs were instructed to identify race/ethnicity barriers and identify interventions that will be implemented to remediate the barriers identified.

These PIPs will extend from January 2019 through December 2022. With research beginning in 2019, initial PIP proposals were developed and submitted in third quarter 2020, with a final report due in October 2023. The non-intervention baseline period was January 2019 to December 2019. Following the formal PIP proposal, the timeline defined for the PIPs includes interim reports in October 2021 and October 2022, as well as a final report in October 2023. For the current review year, 2021, interim reports were due in October. These proposals underwent initial review by IPRO and feedback was provided to plans, with a timeline to resubmit to address areas of concern.

For each PIP, all PH MCOs shared the same baseline period and timeline defined for that PIP. To introduce each PIP cycle, DHS provided specific guidelines that addressed the PIP submission schedule, the measurement period, documentation requirements, topic selection, study indicators, study design, baseline measurement, interventions, re-measurement, and sustained improvement. Direction was given with regard to expectations for PIP relevance, quality, completeness, resubmissions, and timeliness.

As part of the new EQR PIP cycle that was initiated for all Medicaid MCOs in 2020, IPRO adopted the Lean methodology, following the CMS recommendation that QIOs and other healthcare stakeholders embrace Lean in order to promote continuous quality improvement in healthcare.

All PH MCOs were required to submit their projects using a standardized PIP template form, which is consistent with the CMS protocol for *Conducting Performance Improvement Projects*. These protocols follow a longitudinal format and capture information relating to:

- Activity Selection and Methodology
- Data/Results
- Analysis Cycle
- Interventions

Technical Methods of Data Collection and Analysis

IPRO's validation process begins at the PIP proposal phase and continues through the life of the PIP. During the conduct of the PIPs, IPRO provides technical assistance to each MCO/MCP. The technical assistance includes feedback.

CMS's Protocol 1. Validation of Performance Improvement Projects was used as the framework to assess the quality of each PIP, as well as to score the compliance of each PIP with both federal and state requirements. IPRO's assessment involves the following 10 elements:

1. Review of the selected study topic(s) for relevance of focus and for relevance to the MCO/MCP's enrollment.
2. Review of the study question(s) for clarity of statement.
3. Review of the identified study population to ensure it is representative of the MCO/MCP's enrollment and generalizable to the MCO/MCP's total population.

4. Review of selected study indicator(s), which should be objective, clear, unambiguous, and meaningful to the focus of the PIP.
5. Review of sampling methods (if sampling used) for validity and proper technique.
6. Review of the data collection procedures to ensure complete and accurate data were collected.
7. Review of the data analysis and interpretation of study results.
8. Assessment of the improvement strategies for appropriateness.
9. Assessment of the likelihood that reported improvement is “real” improvement.
10. Assessment of whether the MCO/MCP achieved sustained improvement.

Following the review of the listed elements, the review findings are considered to determine whether the PIP outcomes should be accepted as valid and reliable.

Scoring elements and methodology are utilized during the intervention and sustainability periods. MYs 2019 and 2020 were the baseline year and proposal year, and during the 2021 review year, elements were reviewed and scored at multiple points during the year once interim reports were submitted in October 2021. All MCOs received some level of guidance towards improving their proposals in these findings, and MCOs responded accordingly with resubmission to correct specific areas.

For each review element, the assessment of compliance is determined through the weighted responses to each review item. Each element carries a separate weight. Scoring for each element is based on full, partial and non-compliance. Points can be awarded for the two phases of the project noted above and combined to arrive at an overall score. The overall score is expressed in terms of levels of compliance. For the current PIPs, compliance levels were assessed, but no formal scoring was provided.

Table 1.1 presents the terminologies used in the scoring process, their respective definitions, and their weight percentage.

Table 1.1: Element Designation

Element Designation		
Element Designation	Definition	Weight
Full	Met or exceeded the element requirements	100%
Partial	Met essential requirements but is deficient in some areas	50%
Non-compliant	Has not met the essential requirements of the element	0%

When the PIPs are reviewed, all projects are evaluated for the same elements. The scoring matrix is completed for those review elements where activities have occurred during the review year. At the time of the review, a project can be reviewed for only a subset of elements. It will then be evaluated for other elements at a later date, according to the PIP submission schedule. At the time each element is reviewed, a finding is given of “Met”, “Partially Met”, or “Not Met”. Elements receiving a “Met” will receive 100% of the points assigned to the element, “Partially Met” elements will receive 50% of the assigned points, and “Not Met” elements will receive 0%.

Findings

To encourage focus on improving the quality of the projects, PIPs were assessed for compliance on all applicable elements, but were not formally scored. However, the multiple levels of activity and collaboration between DHS, the PH MCOs, and IPRO continued and progressed throughout the implementation of the PIP cycle during the review year.

The Readmission PIP topic was chosen again due to mixed results across MCOs for the current PIP and because the ICP program remains an important initiative. The Opioid PIP was chosen to address the critical issue of increasing opioid use. Following selection of the topics, IPRO worked with DHS to refine the focus and indicators.

For the Readmission PIP, DHS determined that the ICP measures would be defined and collected by the MCOs for the PIP. This was done to address challenges with the previous PIP and to give MCOs more control and increased ability to implement interventions to directly impact their population. Rates for the ICP program are calculated by IPRO annually during late fourth quarter, using PA PROMISe encounters submitted by both the PH MCOs and the BH MCOs. Because the rates are produced late in the year, and because PH MCOs do not have consistent access to BH encounter data, MCOs have experienced some difficulty implementing interventions to have a timely impact on their population. However, to keep the ICP population consistent, MCOs were provided with the methodology used in the program to define members with SPMI. Additionally, as discussions continued around the multiple factors that contribute to preventable admission and readmission, DHS requested that discussion of social determinants of health (SDoH) be included, as the conditions in the places where people live, learn, work, and play affect a wide range of health risks and outcomes; differences in health are striking in communities with poor SDoH.

For the Opioid PIP, in order to develop a comprehensive project, DHS initially selected several measures to focus not only on opioid use but also on measures that might be impacted by changes in opioid use. IPRO researched opioid PIPs in other states and discovered that most attempted to first focus on impacting opioid use metrics. This, coupled with Lean guidance that suggests the use of fewer measures to target interventions and change more directly, led to the selection of HEDIS and CMS opioid-related measures. Upon further internal discussion, DHS wanted to ensure that MCOs were using and incorporating DHS opioid-related initiatives, including the PA Centers of Excellence (COE) for Opioid Use Disorder program and incentives under the DHS Quality Care Hospital Assessment Initiative. To this end, DHS added three process oriented measures related to current PA initiatives.

For both PIPs, in light of the current health crisis and ongoing adverse impacts, DHS required MCOs to expand efforts to address health disparities. For a number of the PIP indicators, the PH MCOs already provide member level data files that are examined by race/ethnicity breakdowns and are part of ongoing quality discussions between DHS and PH MCOs. To expand on this for each PIP project, PH MCOs were instructed that they will need to identify race/ethnicity barriers and identify interventions that will be implemented to remediate the barriers identified.

Throughout 2021, the second year of the cycle, there were several levels of communication provided to MCOs after their Project Proposal submissions and in preparation for their Interim submissions, including:

- MCO-specific review findings for each PIP, including detailed information to assist MCOs in preparing their interim resubmissions.
- Conference calls as requested with each MCO to discuss the PIP interim review findings with key MCO staff assigned to each PIP topic.

In response to the feedback provided. MCOs were requested to revise and resubmit their documents to address the identified issues and to be reviewed again. PIP-specific calls were held with each MCO that experienced continued difficulty, attended by both DHS and IPRO. Additionally, as needed, PA DHS discusses ongoing issues with MCOs as part of their regularly scheduled monitoring calls. As noted above, for the current review year, 2021, MCOs were requested to submit a Project Interim Report, including baseline and updated interim rates. Review teams consisted of one clinical staff member and one analytical staff member. Following initial review, MCOs were asked to update their submission according to the recommendations noted in the findings. **Table A.1.1** of the MCO's interventions for the project can be found in the **Appendix** of this report.

Preventing Inappropriate Use or Overuse of Opioids

United Healthcare's (UHC's) baseline proposal demonstrated that the topic reflects high-volume/high risk conditions for the population under review. The MCO provided statistics that quantified membership with OUD and further characterized opioid use by race, gender, and geographic location.

UHC provided detailed aims and objectives statements, in which they describe the interventions they plan to implement, the targeted populations of the interventions, and how the interventions will improve rates for the performance indicators. UHC selected bold target goals for some measures. Where target goals were more modest, the MCO provided a rationale.

For the Preventing Inappropriate Use or Overuse of Opioids PIP, seven performance measures were predetermined by DHS and were identified in the template distributed across MCOs, some with multiple indicators. Four measures are to be collected via HEDIS or the CMS Core Set. The remaining three were to be defined by the MCO. The information provided by UHC for all measures demonstrates that they are clearly defined and measurable. Following reviewer recommendation, the MCO provided more detail for the MCO-defined indicators. The indicators measure changes in health status, functional status, and satisfaction or processes of care with strong associations with improved outcomes. UHC plans to measure the indicators consistently over time, in order to provide a clear trend with potential actionable information. Additionally, the MCO's study design specifies data collection methodologies that are valid and reliable, along with robust data analysis procedures.

The MCO's barriers for improvement were identified through data analysis and quality improvement processes. UHC highlighted seven robust interventions that were informed by the barrier analysis, and which target member, provider, and MCO levels. Further, the interventions involve outreach to members, coordination of transfer of care, and several programs and therapies to address the lack of members' knowledge on and motivation towards treatment, provider knowledge and appropriate use of clinical practice guidelines, resources for SUD treatment, and availability of medication for particular populations, such as pregnant women of color. Related to the last intervention, UHC provided justification as requested, for the expansion of SUD Maternal Health Homes.

In October 2021, KF submitted an Interim report for this project and reported improvement that surpassed their established goals during the Proposal period. In response, the MCO revised four of its goals at the Interim reporting period. The MCO included initial data for intervention tracking measures (ITMs) across all interventions, with some measures showing declining trends over each quarter.

UHC clearly reported its results of the PIP thus far, including bar graphs which described reporting progress in relationship to target goals. Rates for four submeasures demonstrated improvement and exceeded target goals; UHC revised targets for these measures. Availability, motivation, and access to care due to COVID-19 were identified by the MCO as a factor in results. However, transitions to telehealth and telephonic outreach were expected to have improved after initial decline. **Table A.1.1** of the MCO's interventions for the project can be found in the **Appendix** of this report.

The following recommendations were identified during the Interim Report review process:

- It was recommended that the MCO perform barrier or root cause analysis for ITMs with declining rates and consider revising those associated interventions or creating new interventions that may better impact the associated barrier.
- It was recommended that the MCO include a note in the Discussion section regarding which ITM outreaches, referrals, and follow-ups have been traditionally done via telehealth or telephonically compared to in-person follow ups. This would give an improved view of how COVID may be impacting these interventions.

Reducing Potentially Preventable Hospital Admissions, Readmissions and ED visits

UHC's baseline proposal for this PIP topic included baseline rates with the potential for meaningful impact on member health, functional status, and satisfaction for the population at hand. The MCO provided data specific to their members' utilization of ED, utilization of acute inpatient care, and hospital readmissions. This support demonstrated that the maximum proportion of members in their population would be impacted by the interventions outlined.

The aim and objectives statements that the MCO provided specified performance indicators for improvement with corresponding goals, and objectives that align the aim and goals with the interventions that have been developed. The objectives target UHC members that are at an increased risk, including members with SPMI, diabetes, respiratory conditions, and/or members with co-morbid conditions.

Similar to the Preventing Inappropriate Use or Overuse of Opioids PIP, for the Reducing Potentially Preventable Hospital Admissions, Readmissions, and ED visits PIP, DHS selected eight performance measures to be included in the PIPs across all MCOs. Three measures are to be collected via HEDIS. The remaining five, all ICP measures, are to be defined by the

MCO with certain predetermined parameters. UHC addressed all recommended clarifications. The performance indicators are clearly defined, measurable, and they measure changes in health status, functional status, and satisfaction or processes of care with strong associations with improved outcomes. UHC plans to measure the indicators consistently over time, in order to provide a clear trend with potential actionable information. Additionally, the MCO's study design specifies data collection methodologies that are valid and reliable, along with robust data analysis procedures.

The barrier analysis and subsequent barriers were identified through data analysis and quality improvement processes. UHC provided twelve robust member and provider interventions with active outreach and education to address the identified barriers. Strengths of the PIP include the large number of interventions and variety of approaches that address the performance indicators by focusing on high risk diagnosis and high risk populations. Interventions are directed towards addressing barriers such as provider lack of information on patient compliance including ED utilization, inpatient admission, and readmission, member knowledge deficit regarding urgent vs emergent care and available resources, member knowledge deficit regarding self-management of chronic diagnosis, and fragmented care involving multiple providers without coordination of care.

In October 2021, UHC submitted an Interim report for this project. The plan included an updated target goal for Indicator 1 (Ambulatory Care: Emergency Department Visits) in light of exceptional performance that surpassed the original goal. In addition, during Proposal review it was noted that the MCO developed Aims that address the African American community. The MCO was encouraged at Interim review to include explanation and data to support the statement that this community is a high-risk population for the Indicators in this PIP. Regarding the interventions the plan developed and reported on, UHC provided clear and thorough interpretation of improvement and decreases for associated ITMs. Barriers informing interventions such as patient and provider education could not be added as measurable interventions. The MCO was encouraged to consider ways in which other interventions could be implemented when barriers are identified.

UHC showed improvement in 5 of the 9 performance indicators and reasons for varying ITM performances were well-defined. One indicator exceeded the target goal, and UHC subsequently revised the goal. The MCO also included explanations for changes in baseline numbers/calculations for Indicators 5 and 6. In the Discussion section, UHC provided clear and thorough analysis of results, affecting factors, and several additional barriers found. **Table A.1.1** of the MCO's interventions for the project can be found in the **Appendix** of this report.

The following recommendations were identified during the Interim Report review process:

- It was recommended that the MCO include more modification in interventions for stagnating or worsening performance, especially in low provider outreach rates.

UHC's Project Interim compliance assessment by review element is presented in **Table 1.2**.

Table 1.2: UHC PIP Compliance Assessments

Review Element	Preventing Inappropriate Use or Overuse of Opioids	Reducing Potentially Preventable Hospital Admissions, Readmissions and ED visits
1. Project Topic	Partial	Met
2. Methodology	Partial	Partial
3. Barrier Analysis, Interventions and Monitoring	Partial	Partial
4. Results	Partial	Partial
5. Discussion	Partial	Met
6. Next Steps	N/A	N/A
7. Validity and Reliability of PIP Results	N/A	N/A

PIP: performance improvement project; ED: emergency department.

II: Performance Measures and CAHPS Survey

Objectives

IPRO validated PA-specific performance measures and HEDIS data for each of the Medicaid PH MCOs.

The MCOs were provided with final specifications for the PA Performance Measures from December 2020 to June 2021. Source code, raw data, and rate sheets were submitted by the MCOs to IPRO for review in 2021. A staggered submission was implemented for the performance measures. IPRO conducted an initial validation of each measure including source code review and provided each MCO with formal written feedback. The MCOs were then given the opportunity for resubmission, if necessary, with a limit of four total submissions. Additional resubmissions required discussion with and approval from DHS. Pseudo code was reviewed by IPRO. Raw data were also reviewed for reasonability, and IPRO ran code against these data to validate that the final reported rates were accurate. Additionally, MCOs were provided with comparisons to the previous year’s rates and were requested to provide explanations for highlighted differences. For measures reported as percentages, differences were highlighted for rates that were statistically significant and displayed at least a 3-percentage point difference in observed rates. For measures not reported as percentages (e.g., adult admission measures), differences were highlighted based only on statistical significance, with no minimum threshold.

For the PA performance Birth-related measure, Elective Delivery, rates are typically produced utilizing MCO Birth files in addition to the final Department of Health Birth File. IPRO requested, from each MCO, information on members with a live birth within the measurement year. IPRO would then typically utilize the MCO file in addition to the most recent applicable PA Department of Health Birth File to identify the denominator, numerator, and rate for the measure. However, due to issues with the COVID-19 pandemic the final 2021 (MY 2020) Department of Health Birth File was not available at the time of reporting. This measure was not reported and is therefore not included in this section.

HEDIS MY 2020 measures were validated through a standard HEDIS compliance audit of each PH MCO. The audit protocol includes pre-onsite review of the HEDIS Roadmap, onsite interviews with staff and a review of systems, and post-onsite validation of the Interactive Data Submission System (IDSS). For HEDIS MY 2020, audit activities were performed virtually due to the public health emergency. A Final Audit Report was submitted to NCQA for each MCO. Because the PA-specific performance measures rely on the same systems and staff, no separate review was necessary for validation of PA-specific measures. IPRO conducts a thorough review and validation of source code, data, and submitted rates for the PA-specific measures.

Evaluation of MCO performance is based on both PA-specific performance measures and selected HEDIS measures for the EQR. It is DHS’s practice to report all first-year performance measures for informational purposes. Relevant context regarding reported rates or calculated averages is provided as applicable, including any observed issues regarding implementation, reliability, or variability among MCOs. Additional discussion regarding MCO rates that differ notably from other MCOs will be included in the MCO-specific findings as applicable. A list of the performance measures included in this year’s EQR report is presented in **Table 2.1**.

Table 2.1: Performance Measure Groupings

Source	Measures
Access/Availability to Care	
HEDIS	Adults’ Access to Preventive/Ambulatory Health Services (Ages 20–44 years)
HEDIS	Adults’ Access to Preventive/Ambulatory Health Services (Ages 45–64 years)
HEDIS	Adults’ Access to Preventive/Ambulatory Health Services (Ages 65+ years)
PA EQR	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Ages 1 to 11)
PA EQR	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Ages 12 to 17)
PA EQR	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Total Ages 1 to 17)
Well-Care Visits and Immunizations	
HEDIS	Well-Child Visits in the First 30 Months of Life (15 months \geq 6 Visits)
HEDIS	Well-Child Visits in the First 30 Months of Life (15 to 30 months \geq 2 visits)
HEDIS	Child and Adolescent Well-Care Visits (Ages 3 to 11 years)

Source	Measures
HEDIS	Child and Adolescent Well-Care Visits (Ages 12 to 17 years)
HEDIS	Child and Adolescent Well-Care Visits (Ages 18 to 21 years)
HEDIS	Child and Adolescent Well-Care Visits (Total)
HEDIS	Childhood Immunizations Status (Combination 2)
HEDIS	Childhood Immunizations Status (Combination 3)
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Body Mass Index: Percentile (Ages 3–11 years)
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Body Mass Index: Percentile (Ages 12–17 years)
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Body Mass Index: Percentile (Total)
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Counseling for Nutrition (Ages 3–11 years)
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Counseling for Nutrition (Ages 12–17 years)
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Counseling for Nutrition (Total)
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Counseling for Physical Activity (Ages 3–11 years)
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Counseling for Physical Activity (Ages 12–17 years)
HEDIS	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents— Counseling for Physical Activity (Total)
HEDIS	Immunizations for Adolescents (Combination 1)
EPSDT: Screenings and Follow-up	
HEDIS	Lead Screening in Children (Ages 2 years)
HEDIS	Follow-up Care for Children Prescribed Attention Deficit/Hyperactivity Disorder (ADHD) Medication— Initiation Phase
HEDIS	Follow-up Care for Children Prescribed Attention Deficit/Hyperactivity Disorder (ADHD) Medication— Continuation and Maintenance Phase
PA EQR	Follow-up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication (BH Enhanced)—Initiation Phase
PA EQR	Follow-up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication (BH Enhanced)—Continuation and Maintenance Phase
PA EQR	Developmental Screening in the First Three Years of Life—Total
PA EQR	Developmental Screening in the First Three Years of Life—1 year
PA EQR	Developmental Screening in the First Three Years of Life—2 years
PA EQR	Developmental Screening in the First Three Years of Life—3 years
PA EQR	Follow-up After Emergency Department Visit for Mental Illness (Ages: 18 to 64—ED visits for mental illness, follow-up within 7 days)
PA EQR	Follow-up After Emergency Department Visit for Mental Illness (Ages: 18 to 64—ED visits for mental illness, follow-up within 30 days)
PA EQR	Follow-up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (Ages: 18 to 64—ED visits for AOD abuse or dependence, follow-up within 7 days)
PA EQR	Follow-up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (Ages: 18 to 64—ED visits for AOD abuse or dependence, follow-up within 30 days)
PA EQR	Follow-up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (Ages: 65 and older—ED visits for AOD abuse or dependence, follow-up within 30 days)
PA EQR	Follow-up After Emergency Department Visit for Mental Illness (Ages: 65 and older—ED visits for mental illness, follow-up within 30 days)

Source	Measures
PA EQR	Follow-up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (Ages: 65 and older—ED visits for AOD abuse or dependence, follow-up within 7 days)
PA EQR	Follow-up After Emergency Department Visit for Mental Illness (Ages: 65 and older—ED visits for mental illness, follow-up within 7 days)
Dental Care for Children and Adults	
HEDIS	Annual Dental Visit (Ages 2–20 years)
PA EQR	Annual Dental Visits for Members with Developmental Disabilities (Ages 2–20 years)
PA EQR	Sealant Receipt on Permanent First Molars (≥ 1 molar)
PA EQR	Sealant Receipt on Permanent First Molars (All 4 molars)
PA EQR	Adult Annual Dental Visit ≥ 21 Years (Ages 21–35 years)
PA EQR	Adult Annual Dental Visit ≥ 21 Years (Ages 36–59 years)
PA EQR	Adult Annual Dental Visit ≥ 21 Years (Ages 60–64 years)
PA EQR	Adult Annual Dental Visit ≥ 21 Years (Ages 65 years and older)
PA EQR	Adult Annual Dental Visit ≥ 21 Years (Ages 21 years and older)
PA EQR	Adult Annual Dental Visit: Women with a Live Birth (Ages 21–35 years)
PA EQR	Adult Annual Dental Visit: Women with a Live Birth (Ages 36–59 years)
PA EQR	Adult Annual Dental Visit: Women with a Live Birth (Ages 21–59 years)
Women's Health	
HEDIS	Breast Cancer Screening (Ages 50–74 years)
HEDIS	Cervical Cancer Screening (Ages 21–64 years)
HEDIS	Chlamydia Screening in Women (Total)
HEDIS	Chlamydia Screening in Women (Ages 16–20 years)
HEDIS	Chlamydia Screening in Women (Ages 21–24 years)
HEDIS	Non-Recommended Cervical Cancer Screening in Adolescent Females
PA EQR	Contraceptive Care for All Women: Provision of most or moderately effective contraception (Ages 15 to 20)
PA EQR	Contraceptive Care for All Women: Provision of LARC (Ages 15 to 20)
PA EQR	Contraceptive Care for All Women: Provision of most or moderately effective contraception (Ages 21 to 44)
PA EQR	Contraceptive Care for All Women: Provision of LARC (Ages 21 to 44)
PA EQR	Contraceptive Care for Postpartum Women: Most or moderately effective contraception—3 days (Ages 15 to 20)
PA EQR	Contraceptive Care for Postpartum Women: Most or moderately effective contraception—60 days (Ages 15 to 20)
PA EQR	Contraceptive Care for Postpartum Women: LARC—3 days (Ages 15 to 20)
PA EQR	Contraceptive Care for Postpartum Women: LARC—60 days (Ages 15 to 20)
PA EQR	Contraceptive Care for Postpartum Women: Most or moderately effective contraception—3 days (Ages 21 to 44)
PA EQR	Contraceptive Care for Postpartum Women: Most or moderately effective contraception—60 days (Ages 21 to 44)
PA EQR	Contraceptive Care for Postpartum Women: LARC—3 days (Ages 21 to 44)
PA EQR	Contraceptive Care for Postpartum Women: LARC—60 days (Ages 21 to 44)
Obstetric and Neonatal Care	
HEDIS	Prenatal and Postpartum Care—Timeliness of Prenatal Care
HEDIS	Prenatal and Postpartum Care—Postpartum Care
PA EQR	Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit: Prenatal Screening for Smoking
PA EQR	Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit: Prenatal Screening for Smoking during one of the first two visits (CHIPRA indicator)

Source	Measures
PA EQR	Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit: Prenatal Screening for Environmental Tobacco Smoke Exposure (ETS)
PA EQR	Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit: Prenatal Counseling for Smoking
PA EQR	Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit: Prenatal Counseling for Environmental Tobacco Smoke Exposure (ETS)
PA EQR	Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit: Prenatal Smoking Cessation
PA EQR	Perinatal Depression Screening: Prenatal Screening for Depression
PA EQR	Perinatal Depression Screening: Prenatal Screening for Depression during one of the first two visits (CHIPRA indicator)
PA EQR	Perinatal Depression Screening: Prenatal Screening Positive for Depression
PA EQR	Perinatal Depression Screening: Prenatal Counseling for Depression
PA EQR	Perinatal Depression Screening: Postpartum Screening for Depression
PA EQR	Perinatal Depression Screening: Postpartum Screening Positive for Depression
PA EQR	Perinatal Depression Screening: Postpartum Counseling for Depression
Respiratory Conditions	
HEDIS	Appropriate Testing for Pharyngitis (Ages 3- 17 years)
HEDIS	Appropriate Testing for Pharyngitis (Ages 18-64 years)
HEDIS	Appropriate Testing for Pharyngitis (Ages 65 years and older)
HEDIS	Appropriate Testing for Pharyngitis (Total)
HEDIS	Appropriate Treatment for Upper Respiratory Infection (Ages 3 months – 17 years)
HEDIS	Appropriate Treatment for Upper Respiratory Infection (Ages 18-64 years)
HEDIS	Appropriate Treatment for Upper Respiratory Infection (Ages 65 years and older)
HEDIS	Appropriate Treatment for Upper Respiratory Infection (Total)
HEDIS	Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (Ages 3 months-17 years)
HEDIS	Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (Ages 18-64 years)
HEDIS	Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (Ages 65 years and older)
HEDIS	Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (Total)
HEDIS	Use of Spirometry Testing in the Assessment and Diagnosis of COPD
HEDIS	Pharmacotherapy Management of COPD Exacerbation—Systemic Corticosteroid
HEDIS	Pharmacotherapy Management of COPD Exacerbation—Bronchodilator
HEDIS	Asthma Medication Ratio (5–11 years)
HEDIS	Asthma Medication Ratio (12–18 years)
HEDIS	Asthma Medication Ratio (19–50 years)
HEDIS	Asthma Medication Ratio (51–64 years)
HEDIS	Asthma Medication Ratio (Total)
PA EQR	Asthma in Children and Younger Adults Admission Rate (Ages 2–17 years)—Admission per 100,000 member months
PA EQR	Asthma in Children and Younger Adults Admission Rate (Ages 18–39 years)—Admission per 100,000 member months
PA EQR	Asthma in Children and Younger Adults Admission Rate (Total Ages 2–39 years)—Admission per 100,000 member months
PA EQR	Chronic Obstructive Pulmonary Disease or Asthma in Older Adults Admission Rate (Ages 40 to 64 years)—Admission per 100,000 member months
PA EQR	Chronic Obstructive Pulmonary Disease or Asthma in Older Adults Admission Rate (Ages 65 years and older)—Admission per 100,000 member months
PA EQR	Chronic Obstructive Pulmonary Disease or Asthma in Older Adults Admission Rate (Total 40+ years)—Admission per 100,000 member months
Comprehensive Diabetes Care	

Source	Measures
HEDIS	Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Testing
HEDIS	Comprehensive Diabetes Care: HbA1c Poor Control (> 9.0%)
HEDIS	Comprehensive Diabetes Care: HbA1c Control (< 8.0%)
HEDIS	Comprehensive Diabetes Care: Retinal Eye Exam
HEDIS	Comprehensive Diabetes Care: Blood Pressure Controlled < 140/90 mm Hg
PA EQR	Diabetes Short-Term Complications Admission Rate (Ages 18–64 years)—Admission per 100,000 member months
PA EQR	Diabetes Short-Term Complications Admission Rate (Ages 65+ years)—Admission per 100,000 member months
PA EQR	Diabetes Short-Term Complications Admission Rate (Total Ages 18+ years)—Admission per 100,000 member months
HEDIS	Statin Therapy for Patients With Diabetes: Received Statin Therapy
HEDIS	Statin Therapy for Patients With Diabetes: Statin Adherence 80%
PA EQR	Diabetes Care for People with Serious Mental Illness: Hemoglobin A1c (HbA1c) Poor Control (> 9.0%) (Ages Cohort: 18–64 Years of Ages)
PA EQR	Diabetes Care for People with Serious Mental Illness: Hemoglobin A1c (HbA1c) Poor Control (> 9.0%) (Ages Cohort: 65–75 Years of Ages)
HEDIS	Kidney Health Evaluation for Patients With Diabetes (18–64 years)
HEDIS	Kidney Health Evaluation for Patients With Diabetes (65–74 years)
HEDIS	Kidney Health Evaluation for Patients With Diabetes (75–85 years)
HEDIS	Kidney Health Evaluation for Patients With Diabetes (Total Ages 18–85 years)
Cardiovascular Care	
HEDIS	Persistence of Beta-Blocker Treatment After Heart Attack
HEDIS	Controlling High Blood Pressure (Total Rate)
PA EQR	Heart Failure Admission Rate (Ages 18–64 years)—Admission per 100,000 member months
PA EQR	Heart Failure Admission Rate (Ages 65+ years)—Admission per 100,000 member months
PA EQR	Heart Failure Admission Rate (Total Ages 18+ years)—Admission per 100,000 member months
HEDIS	Statin Therapy for Patients With Cardiovascular Disease: Received Statin Therapy 21–75 years (Male)
HEDIS	Statin Therapy for Patients With Cardiovascular Disease: Received Statin Therapy 40–75 years (Female)
HEDIS	Statin Therapy for Patients With Cardiovascular Disease: Received Statin Therapy Total Rate
HEDIS	Statin Therapy for Patients With Cardiovascular Disease: Statin Adherence 80%—21–75 years (Male)
HEDIS	Statin Therapy for Patients With Cardiovascular Disease: Statin Adherence 80%—40–75 years (Female)
HEDIS	Statin Therapy for Patients With Cardiovascular Disease: Statin Adherence 80%—Total Rate
HEDIS	Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia
HEDIS	Cardiac Rehabilitation Initiation >2 visits in 30 days (Ages 18–64 years)
HEDIS	Cardiac Rehabilitation Initiation >2 visits in 30 days (Ages 65 years and older)
HEDIS	Cardiac Rehabilitation Initiation >2 visits in 30 days (Total 18 years and older)
HEDIS	Cardiac Rehabilitation Engagement 1 >12 visits in 90 days (Ages 18–64 years)
HEDIS	Cardiac Rehabilitation Engagement 1 >12 visits in 90 days (Ages 65 years and older)
HEDIS	Cardiac Rehabilitation Engagement 1 >12 visits in 90 days (Total 18 years and older)
HEDIS	Cardiac Rehabilitation Engagement 2 >24 visits in 180 days (Ages 18–64 years)
HEDIS	Cardiac Rehabilitation Engagement 2 >24 visits in 180 days (Ages 65 years and older)
HEDIS	Cardiac Rehabilitation Engagement 2 >24 visits in 180 days (Total 18 years and older)
HEDIS	Cardiac Rehabilitation Achievement >36 visits in 180 days (Ages 18–64 years)
HEDIS	Cardiac Rehabilitation Achievement >36 visits in 180 days (Ages 65 years and older)
HEDIS	Cardiac Rehabilitation Achievement >36 visits in 180 days (Total 18 years and older)
Utilization	
HEDIS	Adherence to Antipsychotic Medications for Individuals with Schizophrenia
PA EQR	Adherence to Antipsychotic Medications for Individuals with Schizophrenia (BH Enhanced)

Source	Measures
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose Testing (Ages 1–11 years)
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose Testing (Ages 12–17 years)
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose Testing (Total Ages 1–17 years)
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Cholesterol Testing (Ages 1–11 years)
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Cholesterol Testing (Ages 12–17 years)
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Cholesterol Testing (Total Ages 1–17 years)
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose & Cholesterol Testing (Ages 1–11 years)
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose & Cholesterol Testing (Ages 12–17 years)
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose & Cholesterol Testing (Total Ages 1–17 years)
HEDIS	Use of Opioids at High Dosage
HEDIS	Use of Opioids from Multiple Providers (4 or more prescribers)
HEDIS	Use of Opioids from Multiple Providers (4 or more pharmacies)
HEDIS	Use of Opioids from Multiple Providers (4 or more prescribers & pharmacies)
HEDIS	Risk of Continued Opioid Use—New Episode Lasts at Least 15 Days (Ages 18–64 years)
HEDIS	Risk of Continued Opioid Use—New Episode Lasts at Least 15 Days (Ages 65 years and older)
HEDIS	Risk of Continued Opioid Use—New Episode Lasts at Least 15 Days (Total Ages 18 years and older)
HEDIS	Risk of Continued Opioid Use—New Episode Lasts at Least 31 Days (Ages 18–64 years)
HEDIS	Risk of Continued Opioid Use—New Episode Lasts at Least 31 Days (Ages 65 years and older)
HEDIS	Risk of Continued Opioid Use—New Episode Lasts at Least 31 Days (Total Ages 18 years and older)
PA EQR	Concurrent Use of Opioids and Benzodiazepines (Ages 18–64 years)
PA EQR	Concurrent Use of Opioids and Benzodiazepines (Ages 65 years and older)
PA EQR	Concurrent Use of Opioids and Benzodiazepines (Total Ages 18 years and older)
HEDIS	Pharmacotherapy for Opioid Use Disorder (Ages 16–64 years)
HEDIS	Pharmacotherapy for Opioid Use Disorder (Ages 65+ years)
HEDIS	Pharmacotherapy for Opioid Use Disorder (Total Ages 16+ years)
PA EQR	Use of Pharmacotherapy for Opioid Use Disorder (Total)
PA EQR	Use of Pharmacotherapy for Opioid Use Disorder (Buprenorphine)
PA EQR	Use of Pharmacotherapy for Opioid Use Disorder (Oral Naltrexone)
PA EQR	Use of Pharmacotherapy for Opioid Use Disorder (Long-Acting, Injectable Naltrexone)
PA EQR	Use of Pharmacotherapy for Opioid Use Disorder (Methadone)
Utilization (Continued)	
HEDIS	Plan All-Cause Readmissions: Count of Index Hospital Stays (IHS)—Total Stays (Ages Total)
HEDIS	Plan All-Cause Readmissions: Count of 30-Day Readmissions—Total Stays (Ages Total)
HEDIS	Plan All-Cause Readmissions: Observed Readmission Rate—Total Stays (Ages Total)
HEDIS	Plan All-Cause Readmissions: Expected Readmission Rate—Total Stays (Ages Total)
HEDIS	Plan All-Cause Readmissions: Observed to Expected Readmission Ratio—Total Stays (Ages Total)

PA: Pennsylvania; EQR: external quality review; HEDIS: Healthcare Effectiveness Data and Information Set.

PA-Specific and CMS Core Set Performance Measure Selection and Descriptions

Several PA-specific performance measures were calculated by each MCO and validated by IPRO. In accordance with DHS direction, IPRO created the indicator specifications to resemble HEDIS specifications. Measures previously developed and added, as mandated by CMS for children in accordance with the Children’s Health Insurance Program Reauthorization Act (CHIPRA) and for adults in accordance with the Affordable Care Act (ACA), were continued as applicable to revised CMS specifications. Additionally, new measures were developed and added in 2021 as mandated in accordance with the CMS specifications. The CMS measures are known as Core Set measures and are indicated below for children and adults. For each indicator, the eligible population is identified by product line, age, enrollment, anchor date, and event/diagnosis. Administrative numerator positives are identified by date of service, diagnosis/procedure code criteria, as well as other specifications, as needed. For 2021 (MY 2020), these performance measure rates were calculated through one of two methods: (1) administrative, which uses only the MCO’s data systems to identify numerator positives and (2) hybrid, which uses a combination of administrative data and medical record review (MRR) to identify numerator “hits” for rate calculation.

A number of performance measures require the inclusion of PH and BH services. Due to the separation of PH and BH services for Medicaid, DHS requested that IPRO utilize encounters submitted by all PH and BH MCOs to DHS via the PROMISE encounter data system to ensure both types of services were included, as necessary. For some measures, IPRO enhanced PH data submitted by MCOs with BH PROMISE encounter data, while for other measures, IPRO collected and reported the measures using PROMISE encounter data for both the BH and PH data required.

PA-Specific and CMS Core Set Administrative Measures

Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics—CHIPRA Core Set

This performance measure assesses the percentage of children and adolescents 1 to 17 years of age who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as first-line treatment. This measure was collected and reported by IPRO using PROMISE encounter data for the required BH and PH data.

Follow-up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication—CHIPRA Core Set

DHS enhanced this measure using behavioral health (BH) encounter data contained in IPRO’s encounter data warehouse. IPRO evaluated this measure using HEDIS 2021 Medicaid member-level data submitted by the PH MCO.

This performance measure assesses the percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days from the time the first ADHD medication was dispensed. Two rates are reported:

- **Initiation Phase**—The percentage of children 6 to 12 years old as of the Index Prescription Start Date (IPSD) with an ambulatory prescription dispensed for ADHD medication that had one follow-up visit with a practitioner with prescribing authority during the 30-day Initiation Phase.
- **Continuation and Maintenance (C&M) Phase**—The percentage of children 6 to 12 years old as of the IPSD with an ambulatory prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and, who in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.

Developmental Screening in the First Three Years of Life—CHIPRA Core Set

This performance measure assesses the percentage of children screened for risk of developmental, behavioral, and social delays using a standardized screening tool in the 12 months preceding or on their first, second, or third birthday. Four rates—one for each age group and a combined rate—are calculated and reported.

Follow-up After Emergency Department Visit for Mental Illness—Adult Core Set

This performance measure assesses the percentage of emergency department (ED) visits for members 18 years of age and older with a principal diagnosis of mental illness or intentional self-harm and who had a follow-up visit with a corresponding principal diagnosis for mental illness. This measure was collected and reported by IPRO using PROMISE encounter data for the required BH and PH data. Two rates are reported:

- The percentage of ED visits for mental illness for which the member received follow-up within 7 days of the ED visit (8 total days); and
- The percentage of ED visits for mental illness for which the member received follow-up within 30 days of the ED visit (31 total days).

Per the CMS specifications, rates are reported for age cohorts 18 to 64 and 65 and older.

Follow-up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence—Adult Core Set

This performance measure assesses the percentage of emergency department (ED) visits for members 18 years of age and older with a principal diagnosis of alcohol or other drug (AOD) abuse or dependence and who had a follow-up visit with a corresponding principal diagnosis for AOD abuse or dependence. This measure was collected and reported by IPRO using PROMISe encounter data for the required BH and PH data. Two rates are reported:

- The percentage of ED visits for AOD abuse or dependence for which the member received follow-up within 7 days of the ED visit (8 total days); and
- The percentage of ED visits for AOD abuse or dependence for which the member received follow-up within 30 days of the ED visit (31 total days).

Per the CMS specifications, rates are reported for age cohorts 18 to 64 and 65 and older.

Annual Dental Visits for Enrollees with Developmental Disabilities—PA-specific

This performance measure assesses the percentage of enrollees with a developmental disability age 2 through 20 years of age who were continuously enrolled and had at least one dental visit during the measurement year. This indicator utilizes the HEDIS MY 2020 measure Annual Dental Visit (ADV).

Sealant Receipt on Permanent First Molars—CHIPRA Core Set — New for 2021

This performance measure assesses the percentage of enrolled children who have ever received sealants on permanent first molar teeth and turned 10 years old during the measurement year. Two rates are reported:

- The percentage of enrolled children who received a sealant on at least one permanent first molar in the 48 months prior to their 10th birthday; and
- The percentage of unduplicated enrolled children who received sealants on all four permanent first molars in the 48 months prior to their 10th birthday.

Adult Annual Dental Visit ≥ 21 Years—PA-specific

This performance measure assesses two indicators:

- The percentage of enrollees 21 years of age and above who were continuously enrolled during the calendar year 2020. Five rates will be reported: one for each of the four age cohorts (21–35, 36–59, 60–64, and 65+ years) and a total rate.
- The percentage of women 21 years of age and older with a live birth that had at least one dental visit during the measurement year. Three rates will be reported for Indicator 2: one for each of the two age cohorts for women with a live birth (21–39 and 40–59 years) and a total rate.

Contraceptive Care for All Women Ages 15–44—CMS Core Measure

This performance measure assesses the percentage of women ages 15 to 44 at risk of unintended pregnancy who were provided a most effective/moderately effective contraception method or a long-acting reversible method of contraception (LARC). Four rates are reported—two rates for each of the age groups (15–20 and 21–44): (1) provision of most or moderately effective contraception, and (2) provision of LARC.

Contraceptive Care for Postpartum Women Ages 15–44—CMS Core Measure

This performance measure assesses the percentage of women ages 15 to 44 who had a live birth and were provided a most effective/moderately effective contraception method or a long-acting reversible method of contraception (LARC) within 3 days and within 60 days of delivery. Eight rates are reported—four rates for each of the age groups (15–20 and

21–44): (1) Most or moderately effective contraception—3 days, (2) Most or moderately effective contraception—60 days, (3) LARC—3 days, and (4) LARC—60 days.

Asthma in Children and Younger Adults Admission Rate—Adult Core Set and PA-specific

This performance measure assesses the number of discharges for asthma in enrollees ages 2 years to 39 years per 100,000 Medicaid member months. Three age groups are reported: ages 2–17 years, ages 18–39 years, and total ages 2–39 years.

Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Admission Rate—Adult Core Set

This performance measure assesses the number of discharges for chronic obstructive pulmonary disease (COPD) or asthma for Medicaid members 40 years and older per 100,000 member months. Three age groups are reported: ages 40–64 years, age 65 years and older, and 40+ years.

Diabetes Short-Term Complications Admission Rate—Adult Core Set

This performance measure assesses the number of discharges for diabetes short-term complications (ketoacidosis, hyperosmolarity, or coma) in adults 18 years and older per 100,000 Medicaid member months. Three age groups are reported: ages 18–64 years, age 65 years and older, and 18+ years.

Diabetes Care for People with Serious Mental Illness: Hemoglobin A1c (HbA1c) Poor Control (> 9.0%)—Adult Core Set

This performance measure assesses the percentage of beneficiaries ages 18 to 75 with a serious mental illness and diabetes (type 1 and type 2) whose most recent Hemoglobin A1c (HbA1c) level during the measurement years was > 9.0%. This measure was collected and reported by IPRO using PROMISe encounter data for the required BH and PH data.

Heart Failure Admission Rate—Adult Core Set

This performance measure assesses the number of discharges for heart failure in adults 18 years and older per 100,000 Medicaid member months. Three age groups are reported: ages 18–64 years, ages 65 years and older, and 18+ years.

Adherence to Antipsychotic Medications for Individuals with Schizophrenia—Adult Core Set

This performance measure assesses the percentage of members 18 years of age and older with schizophrenia or schizoaffective disorder who were dispensed and remained on an antipsychotic medication for at least 80% of their treatment period during the measurement year. Members in hospice are excluded from the eligible population.

DHS enhanced this measure using behavioral health (BH) encounter data contained in IPRO's encounter data warehouse.

Concurrent Use of Opioids and Benzodiazepines—Adult Core Set

This performance measure assesses the percentage of members 18 years of age and above with concurrent use of prescription opioids and benzodiazepines. Three age groups are reported: ages 18–64 years, age 65 years and older, and 18+ years.

Use of Pharmacotherapy for Opioid Use Disorder—Adult Core Set

This performance measure assesses the percentage of members ages 18 to 64 with an opioid use disorder who filled a prescription for or were administered or dispensed an FDA-approved medication for the disorder during the measurement year. Five rates are reported: a total rate including any medications used in medication-assisted treatment of opioid dependence and addiction, and four separate rates representing the following FDA-approved drug products: (1) buprenorphine; (2) oral naltrexone; (3) long-acting, injectable naltrexone; and (4) methadone.

PA Specific Hybrid Measures

Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit—PA-specific

This performance measure assesses the percentage of pregnant enrollees who were:

1. Screened for smoking during the time frame of one of their first two prenatal visits or during the time frame of their first two visits on or following initiation of eligibility with the MCO.
2. Screened for smoking during the time frame of one of their first two prenatal visits (CHIPRA indicator).

3. Screened for environmental tobacco smoke exposure during the time frame of one of their first two prenatal visits or during the time frame of their first two visits on or following initiation of eligibility with the MCO.
4. Screened for smoking in one of their first two prenatal visits who smoke (i.e., smoked six months prior to or anytime during the current pregnancy), that were given counseling/advice or a referral during the time frame of any prenatal visit during pregnancy.
5. Screened for environmental tobacco smoke exposure in one of their first two prenatal visits and found to be exposed, that were given counseling/advice or a referral during the time frame of any prenatal visit during pregnancy.
6. Screened for smoking in one of their first two prenatal visits and found to be current smokers (i.e., smoked at the time of one of their first two prenatal visits) that stopped smoking during their pregnancy.

This performance measure uses components of the HEDIS MY 2020 Prenatal and Postpartum Care Measure.

Perinatal Depression Screening—PA-specific

This performance measure assesses the percentage of enrollees who were:

1. Screened for depression during a prenatal care visit.
2. Screened for depression during a prenatal care visit using a validated depression screening tool.
3. Screened for depression during the time frame of the first two prenatal care visits (CHIPRA indicator).
4. Screened positive for depression during a prenatal care visit.
5. Screened positive for depression during a prenatal care visit and had evidence of further evaluation, treatment, or referral for further treatment.
6. Screened for depression during a postpartum care visit.
7. Screened for depression during a postpartum care visit using a validated depression screening tool.
8. Screened positive for depression during a postpartum care visit.
9. Screened positive for depression during a postpartum care visit and had evidence of further evaluation, treatment, or referral for further treatment.

This performance measure uses components of the HEDIS MY 2020 Prenatal and Postpartum Care Measure.

HEDIS Performance Measure Selection and Descriptions

Each MCO underwent a full HEDIS compliance audit in 2021. As indicated previously, performance on selected HEDIS measures is included in this year's EQR report. Development of HEDIS measures and the clinical rationale for their inclusion in the HEDIS measurement set can be found in HEDIS MY 2020, Volume 2 Narrative. The measurement year for the HEDIS measures is 2020, as well as prior years for selected measures. Each year, DHS updates its requirements for the MCOs to be consistent with NCQA's requirement for the reporting year. MCOs are required to report the complete set of Medicaid measures, excluding behavioral health and chemical dependency measures, as specified in the HEDIS Technical Specifications, Volume 2. In addition, DHS does not require the MCOs to produce the Chronic Conditions component of the CAHPS 5.1H—Child Survey.

Adults' Access to Preventive/Ambulatory Health Services

This measure assesses the percentage of members 20 years and older who had an ambulatory or preventive care visit during the measurement year (for Medicaid or Medicare). The following age groups are reported: 20–44, 45–64, and 65+.

Adult Body Mass Index (BMI) Assessment

This measure assesses the percentage of members 18–74 years of age who had an outpatient visit and whose body mass index (BMI) was documented during the measurement year or the year prior to the measurement year.

Well-Child Visits in the First 30 Months of Life – New for 2021

This measure assesses the percentage of members who turned 30 months old during the measurement year, who were continuously enrolled from 31 days of age through 30 months of age, and who:

- Received six or more well-child visits with a PCP during their first 15 months of life; and
- Received two or more well-child visits for age 15 months-30 months of life.

Childhood Immunization Status (Combos 2 and 3)

This measure assesses the percentage of children who turned 2 years of age in the measurement year, who were continuously enrolled for the 12 months preceding their second birthday, and who received one or both of two immunization combinations on or before their second birthday. Separate rates were calculated for each Combination. Combination 2 and Combination 3 consist of the following immunizations:

- (4) Diphtheria, Tetanus, and Acellular Pertussis Vaccine/Diphtheria and Tetanus (DTaP/DT);
- (3) Injectable Polio Vaccine (IPV);
- (1) Measles, Mumps, and Rubella (MMR);
- (3) Haemophilus Influenza Type B (HiB);
- (3) Hepatitis B (HepB);
- (1) Chicken Pox (VZV); and
- (4) Pneumococcal Conjugate Vaccine (PCV)—Combination 3 only.

Child and Adolescent Well-Care Visits – New for 2021

This measure assesses the percentage of enrolled members 3–21 years of age who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the measurement year.

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents

This measure assesses the percentage of members 3–17 years of age, who had an outpatient visit with a PCP or OB/GYN, and who had evidence of the following during the measurement year:

- BMI percentile documentation;
- Counseling for nutrition; and
- Counseling for physical activity.

Because BMI norms for youth vary with age and gender, this measure evaluates whether BMI percentile is assessed rather than an absolute BMI value.

Immunization for Adolescents (Combo 1)

This measure assesses the percentage of adolescents 13 years of age who had one dose of meningococcal conjugate vaccine and one tetanus, diphtheria toxoids, and acellular pertussis (Tdap) vaccine by their 13th birthday.

Lead Screening in Children

This measure assesses the percentage of children 2 years of age who had one or more capillary or venous lead blood tests for lead poisoning by their second birthday.

Follow-up Care for Children Prescribed ADHD Medication

This measure assesses the percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed. Two rates are reported:

- **Initiation Phase**—The percentage of members 6–12 years of age as of the IPSD with an ambulatory prescription dispensed for ADHD medication who had one follow-up visit with practitioner with prescribing authority during the 30-day Initiation Phase.
- **Continuation and Maintenance (C&M) Phase**—The percentage of members 6–12 years of age as of the IPSD with an ambulatory prescription dispensed for ADHD medication who remained on the medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.

Annual Dental Visit

This measure assesses the percentage of children and adolescents 2–20 years of age who were continuously enrolled in the MCO for the measurement year and who had at least one dental visit during the measurement year.

Breast Cancer Screening

This measure assesses the percentage of women ages 50–74 who had a mammogram to screen for breast cancer.

The eligible population for this measure is women 52–74 years of age as of December 31 of the measurement year. Members are included in the numerator if they had one or more mammograms any time on or between October 1 in the 2 years prior to the measurement year and December 31 of the measurement year. Eligible members who received mammograms beginning at age 50 are included in the numerator.

Cervical Cancer Screening

This measure assesses the percentage of women 21–64 years of age who were screened for cervical cancer using any of the following criteria:

- Women ages 21–64 who had cervical cytology performed within the last 3 years;
- Women ages 30–64 who had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years; or
- Women ages 30–64 who had cervical cytology/high-risk human papillomavirus (hrHPV) co-testing within the last 5 years.

Chlamydia Screening in Women

This measure assesses the percentage of women 16–24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year. Three age cohorts are reported: 16–20 years, 21–24 years, and total.

Non-Recommended Cervical Cancer Screening in Adolescent Females

This measure assesses the percentage of adolescent females 16–20 years of age who were screened unnecessarily for cervical cancer. For this measure, a lower rate indicates better performance.

Prenatal and Postpartum Care

This measure assesses the percentage of deliveries of live births on or between October 8 of the year prior to the measurement year and October 7 of the measurement year. For these women, the measure assesses the following facets of prenatal and postpartum care:

- Timeliness of Prenatal Care—The percentage of deliveries that received a prenatal care visit in the first trimester, on or before the enrollment start date or within 42 days of enrollment in the organization; and
- Postpartum Care—The percentage of deliveries that had a postpartum visit on or between 7 and 84 days after delivery.

Appropriate Testing for Pharyngitis

This measure assesses the percentage of episodes for members 3 years and older for which the member was diagnosed with pharyngitis, dispensed an antibiotic, and received a group A streptococcus (strep) test for the episode. A higher rate represents better performance (i.e., appropriate testing). The total rate is reported.

Appropriate Treatment for Upper Respiratory Infection

This measure assesses the percentage of episodes for members 3 months of age and older with a diagnosis of upper respiratory infection (URI) that did not result in an antibiotic dispensing event. The measure is reported as an inverted rate ($1 - [\text{numerator}/\text{eligible population}]$). A higher rate indicates appropriate treatment of children with URI (i.e., the proportion for whom antibiotics were not prescribed). The total rate is reported.

Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis

This measure assesses the percentage of episodes for members ages 3 months and older with a diagnosis of acute

bronchitis/bronchiolitis that did not result in an antibiotic dispensing event. The measure is reported as an inverted rate ($1 - [\text{numerator}/\text{eligible population}]$). A higher rate indicates appropriate treatment of adults with acute bronchitis (i.e., the proportion for whom antibiotics were not prescribed). The total rate is reported.

Use of Spirometry Testing in the Assessment and Diagnosis of COPD

This measure assesses the percentage of members 40 years of age and older with a new diagnosis of COPD or newly active COPD who received appropriate spirometry testing to confirm the diagnosis.

Pharmacotherapy Management of COPD Exacerbation

This measure assesses the percentage of COPD exacerbations for members 40 years of age and older who had an acute inpatient discharge or ED visit on or between January 1 and November 30 of the measurement year and who were dispensed appropriate medications. Two rates are reported:

- Dispensed a systemic corticosteroid (or there was evidence of an active prescription) within 14 days of the event; and
- Dispensed a bronchodilator (or there was evidence of an active prescription) within 30 days of the event.

Asthma Medication Ratio

This measure assesses the percentage of members 5–64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year. The following age groups are reported: 5–11 years, 12–18 years, 19–50 years, 51–64 years, and total years.

Comprehensive Diabetes Care

This measure assesses the percentage of members 18–75 years of age with diabetes (type 1 and type 2) who had each of the following:

- Hemoglobin A1c (HbA1c) testing;
- HbA1c poor control ($> 9.0\%$);
- HbA1c control ($< 8.0\%$);
- Eye exam (retinal) performed; and
- BP control ($< 140/90$ mm Hg).

Statin Therapy for Patients with Diabetes

This measure assesses the percentage of members 40–75 years of age during the measurement year with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) who met the following criteria. Two rates are reported:

- Received Statin Therapy—Members who were dispensed at least one statin medication of any intensity during the measurement year; and
- Statin Adherence 80%—Members who remained on a statin medication of any intensity for at least 80% of the treatment period.

Kidney Health Evaluation for Patients with Diabetes — New for 2021

This measure assesses the percentage of members 18–85 years of age with diabetes (type 1 and type 2) who received a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) and a urine albumin-creatinine ratio (uACR), during the measurement year. The following age groups are reported: 18–64 years, 65–74 years, 75–85 years, and total years.

Persistence of Beta-Blocker Treatment After a Heart Attack

This measure assesses the percentage of members 18 years of age and older during the measurement year who were hospitalized and discharged from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of AMI and who received persistent beta-blocker treatment for 6 months after discharge.

Controlling High Blood Pressure

This measure assesses the percentage of members 18–85 years of age who had a diagnosis of hypertension (HTN) and whose BP was adequately controlled during the measurement year.

Statin Therapy for Patients with Cardiovascular Disease

This measure assesses the percentage of males 21–75 years of age and females 40–75 years of age during the measurement year who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria. The following rates are reported:

- Received Statin Therapy—Members who were dispensed at least one high- or moderate-intensity statin medication during the measurement year; and
- Statin Adherence 80%—Members who remained on a high- or moderate-intensity statin medication for at least 80% of the treatment period.

Total rates for both submeasures are also reported.

Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia

This measure assesses the percentage of members 18–64 years of age with schizophrenia or schizoaffective disorder and cardiovascular disease who had an LDL-C test during the measurement year.

Cardiac Rehabilitation — New for 2021

This measure assesses the percentage of members 18 years and older, who attended cardiac rehabilitation following a qualifying cardiac event, including myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, heart and heart/lung transplantation or heart valve repair/replacement. Three age groups (18–64 years, 65 years and older, and total years) are reported for each of the following four rates:

- *Initiation.* The percentage of members who attended 2 or more sessions of cardiac rehabilitation within 30 days after a qualifying event.
- *Engagement 1.* The percentage of members who attended 12 or more sessions of cardiac rehabilitation within 90 days after a qualifying event.
- *Engagement 2.* The percentage of members who attended 24 or more sessions of cardiac rehabilitation within 180 days after a qualifying event.
- *Achievement.* The percentage of members who attended 36 or more sessions of cardiac rehabilitation within 180 days after a qualifying event.

Adherence to Antipsychotic Medications for Individuals with Schizophrenia

This measure assesses the percentage of members 18 years of age and older during the measurement year with schizophrenia or schizoaffective disorder who were dispensed and remained on an antipsychotic medication for at least 80% of their treatment period.

Metabolic Monitoring for Children and Adolescents on Antipsychotics

This measure assesses the percentage of children and adolescents 1–17 years of age who had two or more antipsychotic prescriptions and had metabolic testing. Three rates are reported for each age group (1–11 years, 12–17 years, and total):

- The percentage of children and adolescents on antipsychotics who received blood glucose testing;
- The percentage of children and adolescents on antipsychotics who received cholesterol testing; and
- The percentage of children and adolescents on antipsychotics who received blood glucose and cholesterol testing.

Use of Opioids at High Dosage

This measure assesses the proportion of members 18 years and older who received prescription opioids at a high dosage (average morphine milligram equivalent dose [MME] ≥ 90) for ≥ 15 days during the measurement year.

For this measure, a lower rate indicates better performance.

Use of Opioids from Multiple Providers

This measure assesses the proportion of members 18 years and older who received prescription opioids for ≥ 15 days during the measurement year and who received opioids from multiple providers. Three rates are reported:

- Multiple Prescribers—The proportion of members receiving prescriptions for opioids from four or more different prescribers during the measurement year;
- Multiple Pharmacies—The proportion of members receiving prescriptions for opioids from four or more different pharmacies during the measurement year; and
- Multiple Prescribers and Multiple Pharmacies—The proportion of members receiving prescriptions for opioids from four or more different prescribers and four or more different pharmacies during the measurement year (i.e., the proportion of members who are numerator compliant for both the Multiple Prescribers and Multiple Pharmacies rates).

Risk of Continued Opioid Use

This measure assesses the percentage of members 18 years of age and older who have a new episode of opioid use that puts them at risk for continued opioid use. Two rates are reported:

- The percentage of members with at least 15 days of prescription opioids in a 30-day period; and
- The percentage of members with at least 31 days of prescription opioids in a 62-day period.

Pharmacotherapy for Opioid Use Disorder

This measure assesses the percentage of new opioid use disorder (OUD) pharmacotherapy events with OUD pharmacotherapy for 180 or more days among members age 16 and older with a diagnosis of OUD.

Plan All-Cause Readmissions

The measure assesses, for members ages 18 to 64, the number of acute inpatient and observation stays during the measurement year that were followed by an unplanned acute readmission for any diagnosis within 30 days and the predicted probability of an acute readmission. Data are reported for the total index hospital stays in the following categories:

- Count of Index Hospital Stays (IHS) (denominator);
- Count of 30-Day Readmissions (numerator);
- Observed Readmission Rate;
- Expected Readmissions Rate; and
- Observed to Expected Readmission Ratio.

CAHPS Survey

The Consumer Assessment of Healthcare Providers and Systems (CAHPS) program is overseen by the Agency of Healthcare Research and Quality (AHRQ) and includes many survey products designed to capture consumer and patient perspectives on health care quality. NCQA uses the adult and child versions of the CAHPS Health Plan surveys for HEDIS.

Implementation of PA-Specific Performance Measures and HEDIS Audit

The MCO successfully implemented all of the PA-specific measures for 2021 that were reported with MCO-submitted data. The MCO submitted all required source code and data for review. IPRO reviewed the source code and validated raw data submitted by the MCO. All rates submitted by the MCO were reportable. Rate calculations were collected via rate sheets and reviewed for all of the PA-specific measures. As previously indicated for the Elective Delivery measure, due to issues with the COVID-19 pandemic the final 2021 (MY 2020) Department of Health Birth File was not available for IPRO to calculate the measure at the time of reporting; this measure is not reported.

The MCO successfully completed the HEDIS audit. The MCO received an Audit Designation of Report for all applicable measures.

Conclusions and Comparative Findings

MCO results are presented in **Table 2.2** through **Table 2.12**. For each measure, the denominator, numerator, and measurement year rates with 95% upper and lower confidence intervals (95% CI) are presented. Confidence intervals are ranges of values that can be used to illustrate the variability associated with a given calculation. For any rate, a 95% confidence interval indicates that there is a 95% probability that the calculated rate, if it were measured repeatedly, would

fall within the range of values presented for that rate. All other things being equal, if any given rate were calculated 100 times, the calculated rate would fall within the confidence interval 95 times, or 95% of the time.

Rates for both the measurement year and the previous year are presented, as available (i.e., 2021 [MY 2020] and 2020 [MY 2019]). In addition, statistical comparisons are made between the MY 2020 and MY 2019 rates. For these year-to-year comparisons, the significance of the difference between two independent proportions was determined by calculating the Z ratio. A Z ratio is a statistical measure that quantifies the difference between two percentages when they come from two separate populations. For comparison of MY 2020 rates to MY 2019 rates, statistically significant increases are indicated by “+,” statistically significant decreases by “-,” and no statistically significant change by “n.s.”

In addition to each individual MCO’s rate, the MMC average for 2021 (MY 2020) is presented. The MMC average is a weighted average, which is an average that takes into account the proportional relevance of each MCO. Each table also presents the significance of difference between the plan’s measurement year rate and the MMC average for the same year. For comparison of MY 2020 rates to MMC rates, “+” denotes that the plan rate exceeds the MMC rate, “-” denotes that the MMC rate exceeds the plan rate, and “n.s.” denotes no statistically significant difference between the two rates. Rates for the HEDIS measures were compared to corresponding Medicaid percentiles; comparison results are provided in the tables. The 90th percentile is the benchmark for the HEDIS measures.

Note that the large denominator sizes for many of the analyses led to increased statistical power, and thus contributed to detecting statistical differences that are not clinically meaningful. For example, even a 1-percentage point difference between two rates was statistically significant in many cases, although not meaningful. Hence, results corresponding to each table highlight only differences that are both statistically significant and display at least a 3-percentage point difference in observed rates. It should also be mentioned that when the denominator sizes are small, even relatively large differences in rates might not yield statistical significance due to reduced power; if statistical significance is not achieved, results are not highlighted in the report. Differences are also not discussed if the denominator was less than 30 for a particular rate, in which case, “N/A” (Not Applicable) appears in the corresponding cells. However, “NA” (Not Available) also appears in the cells under the HEDIS MY 2020 percentile column for PA-specific measures that do not have HEDIS percentiles to compare.

Table 2.5 to Table 2.12 show rates up to one decimal place. Calculations to determine differences between rates are based upon unrounded rates. Due to rounding, differences in rates that are reported in the narrative may differ slightly from the difference between rates presented in the table.

As part of IPRO’s validation of UHC’s Performance Measures and CAHPS Survey results, the following are recommended areas of focus for the plan moving into the next reporting year. Particular attention has been paid to measures that are not only identified as opportunities for the current 2021 review year, but were also identified as opportunities in 2020.

- It is recommended that UHC improve access to ambulatory health services for its members. The measure Adults’ Access to Preventive/Ambulatory Health Services was an opportunity in both 2020 and again in 2021 for ages 20-44 and 45-64 years old.
- It is recommended the MCO improve access to services related to women’s health. The following measures were opportunities for improvement in 2020 and again in 2021:
 - Breast Cancer Screening;
 - Cervical Cancer Screening; and
 - Contraceptive Care for Postpartum Women: Most or moderately effective contraception - 60 days (Ages 15 to 20).
- It is recommended the MCO improve access to services for its members on antipsychotic medications. The following measures were opportunities for improvement in 2020 and again in 2021:
 - Adherence to Antipsychotic Medications for Individuals with Schizophrenia;
 - Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose Testing (Ages 12-17 years; 1-17 years);
 - Metabolic Monitoring for Children and Adolescents on Antipsychotics: Cholesterol Testing (Ages 12-17 years; 1-17 years); and

- Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose & Cholesterol Testing (Ages 12-17 years; 1-17 years).
- It is recommended that UHC focus on improving health plan and health care satisfaction for its members who are children. The following items from the MY 2020 CAHPS survey both fell below the MMC weighted average and fell from 2020:
 - Satisfaction with Child's Health Plan (Rating of 8–10);
 - Information or Help from Customer Service (Usually or Always);
 - Satisfaction with Health Care (Rating of 8–10); and
 - Appointment for Routine Care When Needed (Usually or Always).

Access to/Availability of Care

No strengths are identified for the Access to/Availability of Care performance measures.

Opportunities for improvement are identified for the following Access to/Availability of Care measures:

- The following rates are statistically significantly below/worse than the 2021 (MY 2020) MMC weighted average:
 - Adults' Access to Preventive/Ambulatory Health Services (Age 20-44 years) – 5.0 percentage points;
 - Adults' Access to Preventive/Ambulatory Health Services (Age 45-64 years) – 5.4 percentage points.

Table 2.2: Access to/Availability of Care

Indicator Source	Indicator	2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
		Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Adults' Access to Preventive/Ambulatory Health Services (Ages 20-44 years)	63,049	44,230	70.2%	69.8%	70.5%	73.5%	-	75.2%	-	>= 25th and < 50th percentile
HEDIS	Adults' Access to Preventive/Ambulatory Health Services (Ages 45-64 years)	28,022	21,720	77.5%	77.0%	78.0%	80.4%	-	82.9%	-	>= 10th and < 25th percentile
HEDIS	Adults' Access to Preventive/Ambulatory Health Services (Ages 65+ years)	957	677	70.7%	67.8%	73.7%	76.8%	-	73.3%	n.s.	< 10th percentile
PA EQR	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Ages 1 to 11)	81	57	70.4%	59.8%	80.9%	72.2%	n.s.	67.7%	n.s.	NA
PA EQR	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Ages 12 to 17)	200	121	60.5%	53.5%	67.5%	57.1%	n.s.	63.8%	n.s.	NA
PA EQR	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Total ages 1 to 17)	281	178	63.4%	57.5%	69.2%	61.5%	n.s.	65.1%	n.s.	NA

¹ For comparison of MY 2020 rates to MY 2019 rates, statistically significant increases are indicated by "+," statistically significant decreases by "-", and no statistically significant change by "n.s." For comparison of MY 2020 rates to MMC rates, the "+" denotes that the plan rate exceeds the MMC rate, the "-" denotes that the MMC rate exceeds the plan rate, and "n.s." denotes no statistically significant difference between the two rates.

Denom: denominator; Num: numerator; MY: measurement year; MMC: Medicaid Managed Care; HEDIS: Healthcare Effectiveness Data and Information Set; PA: Pennsylvania; EQR: external quality review; NA: not available, as no HEDIS percentile is available to compare.

Well-Care Visits and Immunizations

Strengths are identified for the following Well-Care Visits and Immunizations performance measures:

- The following rates are statistically significantly above/better than the 2021 (MY 2020) MMC weighted average:
 - Body Mass Index: Percentile (Age 3 - 11 years) – 7.6 percentage points;
 - Body Mass Index: Percentile (Age 12-17 years) – 8.3 percentage points;
 - Body Mass Index: Percentile (Total) – 7.8 percentage points;
 - Counseling for Nutrition (Age 3-11 years) – 6.1 percentage points;
 - Counseling for Nutrition (Age 12-17 years) – 10.5 percentage points;
 - Counseling for Nutrition (Total) – 7.6 percentage points;
 - Counseling for Physical Activity (Age 3-11 years) – 7.1 percentage points;
 - Counseling for Physical Activity (Age 12-17 years) – 14.1 percentage points; and
 - Counseling for Physical Activity (Total) – 9.6 percentage points.

No opportunities for improvement are identified for the Well-Care Visits and Immunizations measures.

Table 2.3: Well-Care Visits and Immunizations

Indicator Source	Indicator	2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
		Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Well-Child Visits in the First 30 Months of Life (15 months ≥ 6 Visits)	4,658	2,944	63.2%	61.8%	64.6%	74.2%	-	65.2%	-	≥ 75th and < 90th percentile
HEDIS	Well-Child Visits in the First 30 Months of Life (15-30 months ≥ 2 Visits)	4,477	3,237	72.3%	71.0%	73.6%	N/A	N/A	74.6%	-	≥ 50th and < 75th percentile
HEDIS	Child and Adolescent Well-Care Visits (3-11 years)	41,429	24,425	59.0%	58.5%	59.4%	N/A	N/A	60.5%	-	≥ 50th and < 75th percentile
HEDIS	Child and Adolescent Well-Care Visits (12-17 years)	26,248	13,868	52.8%	52.2%	53.4%	N/A	N/A	54.7%	-	≥ 50th and < 75th percentile
HEDIS	Child and Adolescent Well-Care Visits (18-21 years)	14,312	4,687	32.8%	32.0%	33.5%	N/A	N/A	35.0%	-	≥ 75th and < 90th percentile
HEDIS	Child and Adolescent Well-Care Visits (Total)	81,989	42,980	52.4%	52.1%	52.8%	N/A	N/A	54.6%	-	≥ 50th and < 75th percentile
HEDIS	Childhood Immunizations Status (Combination 2)	411	312	75.9%	71.7%	80.2%	78.3%	n.s.	74.6%	n.s.	≥ 75th and < 90th percentile
HEDIS	Childhood Immunizations Status (Combination 3)	411	301	73.2%	68.8%	77.6%	76.2%	n.s.	72.1%	n.s.	≥ 75th and < 90th percentile

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Weight Assessment & Counseling for Nutrition & Physical Activity for Children/Adolescents – Body Mass Index: Percentile (Age 3 - 11 years)	266	235	88.4%	84.3%	92.4%	87.8%	n.s.	80.8%	+	>= 90th percentile
HEDIS	Weight Assessment & Counseling for Nutrition & Physical Activity for Children/Adolescents – Body Mass Index: Percentile (Age 12- 17 years)	145	123	84.8%	78.6%	91.0%	91.7%	n.s.	76.5%	+	>= 75th and < 90th percentile
HEDIS	Weight Assessment & Counseling for Nutrition & Physical Activity for Children/Adolescents – Body Mass Index: Percentile (Total)	411	358	87.1%	83.7%	90.5%	89.1%	n.s.	79.3%	+	>= 75th and < 90th percentile
HEDIS	Weight Assessment & Counseling for Nutrition & Physical Activity for Children/Adolescents – Counseling for Nutrition (Age 3- 11 years)	266	215	80.8%	75.9%	85.7%	81.7%	n.s.	74.7%	+	>= 75th and < 90th percentile
HEDIS	Weight Assessment & Counseling for Nutrition & Physical Activity for Children/Adolescents – Counseling for Nutrition (Age 12- 17 years)	145	119	82.1%	75.5%	88.7%	78.9%	n.s.	71.6%	+	>= 75th and < 90th percentile
HEDIS	Weight Assessment & Counseling for Nutrition & Physical Activity for Children/Adolescents – Counseling for Nutrition (Total)	411	334	81.3%	77.4%	85.2%	80.8%	n.s.	73.6%	+	>= 75th and < 90th percentile

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Weight Assessment & Counseling for Nutrition & Physical Activity for Children/Adolescents – Counseling for Physical Activity (Age 3-11 years)	266	200	75.2%	69.8%	80.6%	74.8%	n.s.	68.1%	+	>= 75th and < 90th percentile
HEDIS	Weight Assessment & Counseling for Nutrition & Physical Activity for Children/Adolescents – Counseling for Physical Activity (Age 12-17 years)	145	122	84.1%	77.8%	90.4%	79.7%	n.s.	70.0%	+	>= 90th percentile
HEDIS	Weight Assessment & Counseling for Nutrition & Physical Activity for Children/Adolescents – Counseling for Physical Activity (Total)	411	322	78.4%	74.2%	82.5%	76.4%	n.s.	68.8%	+	>= 75th and < 90th percentile
HEDIS	Immunizations for Adolescents (Combo 1)	411	355	86.4%	82.9%	89.8%	89.5%	n.s.	87.6%	n.s.	>= 50th and < 75th percentile

¹ For comparison of MY 2020 rates to MY 2019 rates, statistically significant increases are indicated by “+,” statistically significant decreases by “-,” and no statistically significant change by “n.s.” For comparison of MY 2020 rates to MMC rates, the “+” denotes that the plan rate exceeds the MMC rate, the “-” denotes that the MMC rate exceeds the plan rate, and “n.s.” denotes no statistically significant difference between the two rates.

Denom: denominator; Num: numerator; MY: measurement year; MMC: Medicaid Managed Care; HEDIS: Healthcare Effectiveness Data and Information Set; N/A: not applicable.

EPSDT: Screenings and Follow-up

Strengths are identified for the following EPSDT: Screenings and Follow-up performance measures:

- The following rates are statistically significantly above/better than the 2021 (MY 2020) MMC weighted average:
 - Developmental Screening in the First Three Years of Life - 1 year – 4.7 percentage points.

Opportunities for improvement are identified for the following EPSDT: Screenings and Follow-up measures:

- The following rates are statistically significantly below/worse than the 2021 (MY 2020) MMC weighted average:
 - Follow-up Care for Children Prescribed ADHD Medication - Initiation Phase – 4.4 percentage points;
 - Follow-up Care for Children Prescribed ADHD Medication (BH Enhanced) - Initiation Phase – 4.1 percentage points;
 - Follow-Up After Emergency Department Visit for Mental Illness or Alcohol and Other Drug Abuse or Dependence (Ages: 18 to 64 - ED visits for mental illness, follow-up within 7 days) – 6.0 percentage points; and

- Follow-Up After Emergency Department Visit for Mental Illness or Alcohol and Other Drug Abuse or Dependence (Ages: 18 to 64 - ED visits for mental illness, follow-up within 30 days) – 6.9 percentage points.

Table 2.4: EPSDT: Screenings and Follow-up

Indicator Source	Indicator	2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
		Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Lead Screening in Children (Age 2 years)	411	332	80.8%	76.8%	84.7%	79.8%	n.s.	83.2%	n.s.	>= 75th and < 90th percentile
HEDIS	Follow-up Care for Children Prescribed ADHD Medication—Initiation Phase	1,146	494	43.1%	40.2%	46.0%	29.4%	+	47.5%	-	>= 25th and < 50th percentile
HEDIS	Follow-up Care for Children Prescribed ADHD Medication—Continuation Phase	325	165	50.8%	45.2%	56.4%	37.6%	+	52.8%	n.s.	>= 25th and < 50th percentile
PA EQR	Follow-up Care for Children Prescribed ADHD Medication (BH Enhanced)—Initiation Phase	1,272	550	43.2%	40.5%	46.0%	32.3%	+	47.4%	-	NA
PA EQR	Follow-up Care for Children Prescribed ADHD Medication (BH Enhanced)—Continuation Phase	348	173	49.7%	44.3%	55.1%	40.1%	+	52.3%	n.s.	NA
PA EQR	Developmental Screening in the First Three Years of Life—Total	13,664	8,305	60.8%	60.0%	61.6%	59.5%	+	59.6%	+	NA
PA EQR	Developmental Screening in the First Three Years of Life—1 year	4,346	2,616	60.2%	58.7%	61.7%	57.1	+	55.5%	+	NA
PA EQR	Developmental Screening in the First Three Years of Life—2 years	4,707	2,834	60.2%	58.8%	61.6%	61.4	+	60.7%	n.s.	NA
PA EQR	Developmental Screening in the First Three Years of Life—3 years	4,611	2,855	61.9%	60.5%	63.3%	59.8	+	62.8%	n.s.	NA
PA EQR	Follow-up After Emergency Department Visit for Mental Illness (Ages: 18 to 64—ED visits for mental illness, follow-up within 7 days)	950	346	36.4%	33.3%	39.5%	32.9%	n.s.	42.4%	-	NA
PA EQR	Follow-up After Emergency Department Visit for Mental Illness (Ages: 18 to 64—ED visits for mental illness, follow-up within 30 days)	950	458	48.2%	45.0%	51.4%	46.3%	n.s.	55.1%	-	NA
PA EQR	Follow-up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (Ages: 18 to 64—ED visits for AOD abuse or dependence, follow-up within 7 days)	2,101	437	20.8%	19.0%	22.6%	16.4%	+	21.8%	n.s.	NA
PA EQR	Follow-up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (Ages: 18 to 64—ED visits for AOD abuse or dependence, follow-up within 30 days)	2,101	642	30.6%	28.6%	32.6%	24.4%	+	31.5%	n.s.	NA

Indicator Source	Indicator	2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
		Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
PA EQR	Follow-up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (Ages: 65 and older—ED visits for AOD abuse or dependence, follow-up within 30 days)	2	1	N/A	N/A	N/A	N/A	N/A	11.8%	N/A	NA
PA EQR	Follow-up After Emergency Department Visit for Mental Illness (Ages: 65 and older—ED visits for mental illness, follow-up within 30 days)	0	0	N/A	N/A	N/A	N/A	N/A	85.7%	N/A	NA
PA EQR	Follow-up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (Ages: 65 and older—ED visits for AOD abuse or dependence, follow-up within 7 days)	2	1	N/A	N/A	N/A	N/A	N/A	11.8%	N/A	NA
PA EQR	Follow-up After Emergency Department Visit for Mental Illness (Ages: 65 and older—ED visits for mental illness, follow-up within 7 days)	0	0	N/A	N/A	N/A	N/A	N/A	85.7%	N/A	NA

¹ For comparison of MY 2020 rates to MY 2019 rates, statistically significant increases are indicated by “+,” statistically significant decreases by “-,” and no statistically significant change by “n.s.” For comparison of MY 2020 rates to MMC rates, the “+” denotes that the plan rate exceeds the MMC rate, the “-” denotes that the MMC rate exceeds the plan rate, and “n.s.” denotes no statistically significant difference between the two rates.

Denom: denominator; Num: numerator; MY: measurement year; MMC: Medicaid Managed Care; HEDIS: Healthcare Effectiveness Data and Information Set; PA: Pennsylvania; EQR: external quality review; NA: not available, as no HEDIS percentile is available to compare; 2021 Rate N/A: not applicable, as denominator is less than 30; N/A: not applicable.

Dental Care for Children and Adults

Strengths are identified for the following Dental Care for Children and Adults performance measures:

- The following rates are statistically significantly above/better than the 2021 (MY 2020) MMC weighted average:
 - Sealant Receipt on Permanent First Molars (≥ 1 Molar) – 5.5 percentage points.

Opportunities for improvement are identified for the following Dental Care for Children and Adults measures:

- The following rates are statistically significantly below/worse than the 2021 (MY 2020) MMC weighted average:
 - Annual Dental Visits for Members with Developmental Disabilities (Age 2-20 years) – 5.0 percentage points.

Table 2.5: EPSDT: Dental Care for Children and Adults

Indicator Source	Indicator	2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
		Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Annual Dental Visit (Ages 2–20 years)	83,878	45,426	54.2%	53.8%	54.5%	61.5%	-	54.2%	n.s.	>= 75th and < 90th percentile
PA EQR	Annual Dental Visits for Members with Developmental Disabilities (Ages 2–20 years)	5,657	2,857	50.5%	49.2%	51.8%	59.5%	-	55.5%	-	NA
PA EQR	Sealant Receipt on Permanent First Molars (≥ 1 Molar)	4,458	1,639	36.8%	35.3%	38.2%	N/A	N/A	31.3%	+	NA
PA EQR	Sealant Receipt on Permanent First Molars (All 4 Molars)	4,458	1,016	22.8%	21.5%	24.0%	N/A	N/A	20.9%	+	NA
PA EQR	Adult Annual Dental Visit ≥ 21 Years (Ages 21–35 years)	41,743	10,481	25.1%	24.7%	25.5%	31.4%	-	27.4%	-	NA
PA EQR	Adult Annual Dental Visit ≥ 21 Years (Ages 36–59 years)	39,499	9,176	23.2%	22.8%	23.6%	28.6%	-	25.0%	-	NA
PA EQR	Adult Annual Dental Visit ≥ 21 Years (Ages 60–64 years)	6,257	1,218	19.5%	18.5%	20.5%	23.6%	-	21.4%	-	NA
PA EQR	Adult Annual Dental Visit ≥ 21 Years (Ages 65 years and older)	957	133	13.9%	11.7%	16.1%	17.8%	-	15.0%	n.s.	NA
PA EQR	Adult Annual Dental Visit ≥ 21 Years (Ages 21 years and older)	88,456	21,008	23.8%	23.5%	24.0%	29.4%	-	25.7%	-	NA
PA EQR	Adult Annual Dental Visit Women with a Live Birth (Ages 21-35 years)	2,691	725	26.9%	25.2%	28.6%	N/A	N/A	29.1%	-	NA
PA EQR	Adult Annual Dental Visit Women with a Live Birth (Ages 36-59 years)	304	86	28.3%	23.1%	33.5%	N/A	N/A	29.7%	n.s.	NA
PA EQR	Adult Annual Dental Visit Women with a Live Birth (Ages 21-59 years)	2,995	811	27.1%	25.5%	28.7%	N/A	N/A	29.1%	-	NA

¹ For comparison of MY 2020 rates to MY 2019 rates, statistically significant increases are indicated by “+,” statistically significant decreases by “-,” and no statistically significant change by “n.s.” For comparison of MY 2020 rates to MMC rates, the “+” denotes that the plan rate exceeds the MMC rate, the “-” denotes that the MMC rate exceeds the plan rate, and “n.s.” denotes no statistically significant difference between the two rates.

Denom: denominator; Num: numerator; MY: measurement year; MMC: Medicaid Managed Care; HEDIS: Healthcare Effectiveness Data and Information Set; NA: not available, as no HEDIS percentile is available to compare; N/A: not applicable; PA: Pennsylvania; EQR: external quality review.

Women's Health

No strengths are identified for the Women's Health performance measures.

Opportunities for improvement are identified for the following Women's Health measures:

- The following rates are statistically significantly below/worse than the 2021 (MY 2020) MMC weighted average:
 - Breast Cancer Screening (Age 50-74 years) – 5.0 percentage points;
 - Cervical Cancer Screening (Age 21-64 years) – 4.2 percentage points;
 - Contraceptive Care for Postpartum Women: Most or moderately effective contraception - 3 days (Ages 15 to 20) – 4.6 percentage points; and
 - Contraceptive Care for Postpartum Women: Most or moderately effective contraception - 60 days (Ages 15 to 20) – 7.9 percentage points.

Table 2.6: Women's Health

Indicator Source	Indicator	2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
		Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Breast Cancer Screening (Ages 50–74 years)	6,353	3,061	48.2%	46.9%	49.4%	52.8%	-	53.2%	-	>= 25th and < 50th percentile
HEDIS	Cervical Cancer Screening (Ages 21–64 years)	411	234	56.9%	52.0%	61.8%	59.4%	n.s.	61.1%	-	>= 25th and < 50th percentile
HEDIS	Chlamydia Screening in Women (Total)	8,894	4,945	55.6%	54.6%	56.6%	61.5%	-	57.0%	n.s.	>= 50th and < 75th percentile
HEDIS	Chlamydia Screening in Women (Ages 16–20 years)	4,949	2,532	51.2%	49.8%	52.6%	57.7%	-	53.7%	-	>= 50th and < 75th percentile
HEDIS	Chlamydia Screening in Women (Ages 21–24 years)	3,945	2,413	61.2%	59.6%	62.7%	66.4%	-	61.0%	n.s.	>= 50th and < 75th percentile
HEDIS	Non-Recommended Cervical Cancer Screening in Adolescent Females ²	9,531	21	0.2%	0.1%	0.3%	0.3%	n.s.	0.4%	-	>= 75th and < 90th percentile
PA EQR	Contraceptive Care for All Women: Provision of most or moderately effective contraception (Ages 15 to 20)	11,331	3,400	30.0%	29.2%	30.9%	31.3%	-	31.3%	-	NA
PA EQR	Contraceptive Care for All Women: Provision of LARC (Ages 15 to 20)	11,331	392	3.5%	3.1%	3.8%	4.0%	-	3.3%	n.s.	NA
PA EQR	Contraceptive Care for All Women: Provision of most or moderately effective contraception (Ages 21 to 44)	30,803	8,076	26.2%	25.7%	26.7%	27.3%	-	27.6%	-	NA
PA EQR	Contraceptive Care for All Women: Provision of LARC (Ages 21 to 44)	30,803	1,302	4.2%	4.0%	4.5%	4.6%	-	4.4%	n.s.	NA

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
PA EQR	Contraceptive Care for Postpartum Women: Most or moderately effective contraception—3 days (Ages 15 to 20)	369	43	11.7%	8.2%	15.1%	11.5%	n.s.	16.2%	-	NA
PA EQR	Contraceptive Care for Postpartum Women: Most or moderately effective contraception—60 days (Ages 15 to 20)	369	145	39.3%	34.2%	44.4%	39.1%	n.s.	47.2%	-	NA
PA EQR	Contraceptive Care for Postpartum Women: LARC—3 days (Ages 15 to 20)	369	26	7.0%	4.3%	9.8%	7.3%	n.s.	9.2%	n.s.	NA
PA EQR	Contraceptive Care for Postpartum Women: LARC—60 days (Ages 15 to 20)	369	54	14.6%	10.9%	18.4%	14.6%	n.s.	16.8%	n.s.	NA
PA EQR	Contraceptive Care for Postpartum Women: Most or moderately effective contraception—3 days (Ages 21 to 44)	3,001	562	18.7%	17.3%	20.1%	16.8%	+	19.3%	n.s.	NA
PA EQR	Contraceptive Care for Postpartum Women: Most or moderately effective contraception—60 days (Ages 21 to 44)	3,001	1,300	43.3%	41.5%	45.1%	42.3%	n.s.	44.8%	n.s.	NA
PA EQR	Contraceptive Care for Postpartum Women: LARC—3 days (Ages 21 to 44)	3,001	165	5.5%	4.7%	6.3%	4.1%	+	5.7%	n.s.	NA
PA EQR	Contraceptive Care for Postpartum Women: LARC—60 days (Ages 21 to 44)	3,001	352	11.7%	10.6%	12.9%	10.7%	n.s.	12.4%	n.s.	NA

¹ For comparison of MY 2020 rates to MY 2019 rates, statistically significant increases are indicated by “+,” statistically significant decreases by “-,” and no statistically significant change by “n.s.” For comparison of MY 2020 rates to MMC rates, the “+” denotes that the plan rate exceeds the MMC rate, the “-” denotes that the MMC rate exceeds the plan rate, and “n.s.” denotes no statistically significant difference between the two rates.

² For the Non-Recommended Cervical Cancer Screening in Adolescent Females measure, lower rate indicates better performance.

Denom: denominator; Num: numerator; MY: measurement year; MMC: Medicaid Managed Care; HEDIS: Healthcare Effectiveness Data and Information Set; PA: Pennsylvania; EQR: external quality review; NA: not available, as no HEDIS percentile is available to compare.

Obstetric and Neonatal Care

Strengths are identified for the following Obstetric and Neonatal Care performance measures:

- The following rates are statistically significantly above/better than the 2021 (MY 2020) MMC weighted average:
 - Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit: Prenatal Screening for Smoking – 13.2 percentage points;
 - Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit: Prenatal Screening for Smoking during one of the first two visits (CHIPRA indicator) – 11.0 percentage points;
 - Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit: Prenatal Screening for Environmental Tobacco Smoke Exposure – 13.4 percentage points;
 - Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit: Prenatal Counseling for Smoking – 8.1 percentage points;
 - Perinatal Depression Screening: Prenatal Screening for Depression – 19.5 percentage points;
 - Perinatal Depression Screening: Prenatal Screening for Depression during one of the first two visits (CHIPRA indicator) – 23.2 percentage points;
 - Perinatal Depression Screening: Prenatal Screening Positive for Depression – 6.9 percentage points; and
 - Perinatal Depression Screening: Postpartum Screening for Depression – 20.8 percentage points.

No opportunities for improvement are identified for the Obstetric and Neonatal Care measures.

Table 2.7: Obstetric and Neonatal Care

Indicator Source	Indicator	2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
		Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Prenatal and Postpartum Care—Timeliness of Prenatal Care	411	367	89.3%	86.2%	92.4%	93.2%	-	88.9%	n.s.	>= 75th and < 90th percentile
HEDIS	Prenatal and Postpartum Care—Postpartum Care	411	325	79.1%	75.0%	83.1%	78.1%	n.s.	77.8%	n.s.	>= 50th and < 75th percentile
PA EQR	Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit: Prenatal Screening for Smoking	405	361	89.1%	86.0%	92.3%	N/A	N/A	75.9%	+	NA
PA EQR	Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit: Prenatal Screening for Smoking during one of the first two visits (CHIPRA indicator)	405	348	85.9%	82.4%	89.4%	N/A	N/A	74.9%	+	NA

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
PA EQR	Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit: Prenatal Screening for Environmental Tobacco Smoke Exposure	405	246	60.7%	55.9%	65.6%	N/A	N/A	47.4%	+	NA
PA EQR	Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit: Prenatal Counseling for Smoking	145	128	88.3%	82.7%	93.9%	N/A	N/A	80.2%	+	NA
PA EQR	Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit: Prenatal Counseling for Environmental Tobacco Smoke Exposure	74	61	82.4%	73.1%	91.8%	N/A	N/A	80.0%	n.s.	NA
PA EQR	Prenatal Screening for Smoking and Treatment Discussion During a Prenatal Visit: Prenatal Smoking Cessation	100	32	32.0%	22.4%	41.6%	N/A	N/A	23.6%	n.s.	NA
PA EQR	Perinatal Depression Screening: Prenatal Screening for Depression	405	347	85.7%	82.1%	89.2%	N/A	N/A	66.2%	+	NA
PA EQR	Perinatal Depression Screening: Prenatal Screening for Depression during one of the first two visits (CHIPRA indicator)	405	311	76.8%	72.6%	81.0%	N/A	N/A	53.6%	+	NA
PA EQR	Perinatal Depression Screening: Prenatal Screening Positive for Depression	347	99	28.5%	23.6%	33.4%	N/A	N/A	21.6%	+	NA
PA EQR	Perinatal Depression Screening: Prenatal Counseling for Depression	99	81	81.8%	73.7%	89.9%	N/A	N/A	77.9%	n.s.	NA

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
PA EQR	Perinatal Depression Screening: Postpartum Screening for Depression	324	299	92.3%	89.2%	95.3%	N/A	N/A	71.4%	+	NA
PA EQR	Perinatal Depression Screening: Postpartum Screening Positive for Depression	299	56	18.7%	14.1%	23.3%	N/A	N/A	17.4%	n.s.	NA
PA EQR	Perinatal Depression Screening: Postpartum Counseling for Depression	56	52	92.9%	85.2%	100.0%	N/A	N/A	85.1%	n.s.	NA

¹ For comparison of MY 2020 rates to MY 2019 rates, statistically significant increases are indicated by “+,” statistically significant decreases by “-,” and no statistically significant change by “n.s.” For comparison of MY 2020 rates to MMC rates, the “+” denotes that the plan rate exceeds the MMC rate, the “-” denotes that the MMC rate exceeds the plan rate, and “n.s.” denotes no statistically significant difference between the two rates.

Denom: denominator; Num: numerator; MY: measurement year; MMC: Medicaid Managed Care; HEDIS: Healthcare Effectiveness Data and Information Set; NA: not available, as no HEDIS percentile is available to compare; N/A: not applicable; PA: Pennsylvania; EQR: external quality review.

Respiratory Conditions

Strengths are identified for the following Respiratory Conditions performance measures:

- The following rates are statistically significantly above/better than the 2021 (MY 2020) MMC weighted average:
 - Appropriate Testing for Pharyngitis (Age 3-17 years) – 4.0 percentage points;
 - Appropriate Testing for Pharyngitis (Age 18-64 years) – 6.3 percentage points; and
 - Appropriate Testing for Pharyngitis (Total) – 4.5 percentage points.

Opportunities for improvement are identified for the following Respiratory Conditions measures:

- The following rates are statistically significantly below/worse than the 2021 (MY 2020) MMC weighted average:
 - Chronic Obstructive Pulmonary Disease or Asthma in Older Adults Admission Rate (Age 40 to 64 years) per 100,000 member months – 7.1 percentage points;
 - Chronic Obstructive Pulmonary Disease or Asthma in Older Adults Admission Rate (Age 65 years and older) per 100,000 member months – 6.5 percentage points; and
 - Chronic Obstructive Pulmonary Disease or Asthma in Older Adults Admission Rate (Total Age 40+) per 100,000 member months – 7.1 percentage points.

Table 2.8: Respiratory Conditions

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Appropriate Testing for Pharyngitis (Total—Ages 3 - 17 years)	4,232	3,641	86.0%	85.0%	87.1%	87.7%	-	82.1%	+	>= 75th and < 90th percentile
HEDIS	Appropriate Testing for Pharyngitis (Ages 18-64 years)	2,408	1,587	65.9%	64.0%	67.8%	67.2%	n.s.	59.6%	+	>= 50th and < 75th percentile
HEDIS	Appropriate Testing for Pharyngitis (Ages 65+ years)	3	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NA
HEDIS	Appropriate Testing for Pharyngitis (Total)	6,643	5,228	78.7%	77.7%	79.7%	81.4%	-	74.2%	+	>= 50th and < 75th percentile
HEDIS	Appropriate Treatment for Upper Respiratory Infection (Ages 3 months-17 years) ²	14,198	697	95.1%	94.7%	95.4%	93.5%	+	94.2%	+	>= 75th and < 90th percentile
HEDIS	Appropriate Treatment for Upper Respiratory Infection (Ages 18-64 years) ²	5,398	905	83.2%	82.2%	84.2%	80.4%	+	82.0%	n.s.	>= 50th and < 75th percentile
HEDIS	Appropriate Treatment for Upper Respiratory Infection (Ages 65+ years) ²	26	10	N/A	N/A	N/A	74.2%	N/A	77.8%	N/A	>= 10th and < 25th percentile
HEDIS	Appropriate Treatment for Upper Respiratory Infection (Total) ²	19,622	1,612	91.8%	91.4%	92.2%	90.1%	+	90.9%	+	>= 50th and < 75th percentile
HEDIS	Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (Ages 3 months-17 years) ³	1,582	371	76.6%	74.4%	78.7%	73.5%	+	73.8%	n.s.	>= 75th and < 90th percentile
HEDIS	Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (Ages 18-64 years) ³	1,497	852	43.1%	40.5%	45.6%	45.4%	n.s.	46.3%	n.s.	>= 50th and < 75th percentile
HEDIS	Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (Ages 65+ years) ³	9	6	N/A	N/A	N/A	N/A	N/A	N/A	N/A	>= 25th and < 50th percentile
HEDIS	Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (Total) ³	3,088	1,229	60.2%	58.5%	61.9%	60.3%	n.s.	60.7%	n.s.	>= 50th and < 75th percentile

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	500	127	25.4%	21.5%	29.3%	26.1%	n.s.	26.9%	n.s.	>= 25th and < 50th percentile
HEDIS	Pharmacotherapy Management of COPD Exacerbation: Systemic Corticosteroid	584	448	76.7%	73.2%	80.2%	72.4%	n.s.	77.2%	n.s.	>= 75th and < 90th percentile
HEDIS	Pharmacotherapy Management of COPD Exacerbation: Bronchodilator	584	490	83.9%	80.8%	87.0%	84.1%	n.s.	87.3%	n.s.	>= 25th and < 50th percentile
HEDIS	Asthma Medication Ratio (5–11 years)	695	522	75.1%	71.8%	78.4%	67.9%	+	77.6%	n.s.	>= 10th and < 25th percentile
HEDIS	Asthma Medication Ratio (12–18 years)	714	479	67.1%	63.6%	70.6%	63.3%	n.s.	71.0%	n.s.	>= 25th and < 50th percentile
HEDIS	Asthma Medication Ratio (19–50 years)	1,142	612	53.6%	50.7%	56.5%	49.9%	n.s.	56.7%	n.s.	>= 25th and < 50th percentile
HEDIS	Asthma Medication Ratio (51–64 years)	366	208	56.8%	51.6%	62.0%	53.2%	n.s.	57.6%	n.s.	>= 25th and < 50th percentile
HEDIS	Asthma Medication Ratio (Total)	2,917	1,821	62.4%	60.7%	64.2%	58.5%	+	64.8%	-	>= 25th and < 50th percentile
PA EQR	Asthma in Children and Younger Adults Admission Rate (Ages 2–17 years) per 100,000 member months ⁴	947,444	58	6.1	N/A	N/A	12.7	-	7.1	-	NA
PA EQR	Asthma in Children and Younger Adults Admission Rate (Ages 18–39 years) per 100,000 member months ⁴	918,130	71	7.7	N/A	N/A	7.5	+	5.7	+	NA
PA EQR	Asthma in Children and Younger Adults Admission Rate (Total Ages 2–39 years) per 100,000 member months ⁴	1,865,574	129	6.9	N/A	N/A	10.3	-	6.5	+	NA
PA EQR	Chronic Obstructive Pulmonary Disease or Asthma in Older Adults Admission Rate (Ages 40 to 64 years) per 100,000 member months ⁴	532,651	260	48.8	N/A	N/A	62.1	-	41.8	+	NA

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
PA EQR	Chronic Obstructive Pulmonary Disease or Asthma in Older Adults Admission Rate (Ages 65 years and older) per 100,000 member months ⁴	13,151	7	53.2	N/A	N/A	72.7	-	46.7	+	NA

¹ For comparison of MY 2020 rates to MY 2019 rates, statistically significant increases are indicated by “+,” statistically significant decreases by “-,” and no statistically significant change by “n.s.” For comparison of MY 2020 rates to MMC rates, the “+” denotes that the plan rate exceeds the MMC rate, the “-” denotes that the MMC rate exceeds the plan rate, and “n.s.” denotes no statistically significant difference between the two rates.

² Per NCQA, a higher rate indicates appropriate treatment of children with URI (i.e., the proportion for whom antibiotics were not prescribed).

³ Per NCQA, a higher rate indicates appropriate treatment of adults with acute bronchitis (i.e., the proportion for whom antibiotics were not prescribed).

⁴ For the Admission Rate measures, lower rates indicate better performance.

Denom: denominator; Num: numerator; MY: measurement year; MMC: Medicaid Managed Care; HEDIS: Healthcare Effectiveness Data and Information Set; PA: Pennsylvania; EQR: external quality review; NA: not available, as no HEDIS percentile is available to compare; 2021 Rate N/A: not applicable, as denominator is less than 30; N/A: not applicable.

Comprehensive Diabetes Care

Strengths are identified for the following Comprehensive Diabetes Care performance measures:

- The following rates are statistically significantly above/better than the 2021 (MY 2020) MMC weighted average:
 - Diabetes Care for People with Serious Mental Illness: Hemoglobin A1c (HbA1c) Poor Control (>9.0%) (Age Cohort: 18 - 64 Years of Age) – 10.5 percentage points.

Opportunities for improvement are identified for the following Comprehensive Diabetes Care performance measures:

- The following rates are statistically significantly below/worse than the 2021 (MY 2020) MMC weighted average:
 - Statin Therapy for Patients With Diabetes: Statin Adherence 80% – 4.3 percentage points.

Table 2.9: Comprehensive Diabetes Care

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Comprehensive Diabetes Care – Hemoglobin A1c (HbA1c) Testing	411	338	82.2%	78.4%	86.1%	90.3%	-	83.7%	n.s.	>= 25th and < 50th percentile
HEDIS	Comprehensive Diabetes Care – HbA1c Poor Control (> 9.0%) ²	411	154	37.5%	32.7%	42.3%	30.6%	+	38.4%	n.s.	>= 75th and < 90th percentile

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Comprehensive Diabetes Care – HbA1c Control (< 8.0%)	411	211	51.3%	46.4%	56.3%	57.1%	n.s.	51.2%	n.s.	>= 75th and < 90th percentile
HEDIS	Comprehensive Diabetes Care – Retinal Eye Exam	411	218	53.0%	48.1%	58.0%	58.9%	n.s.	53.3%	n.s.	>= 50th and < 75th percentile
HEDIS	Comprehensive Diabetes Care – Blood Pressure Controlled < 140/90 mm Hg	411	282	68.6%	64.0%	73.2%	71.5%	n.s.	66.0%	+	>= 75th and < 90th percentile
PA EQR	Diabetes Short-Term Complications Admission Rate (Ages 18 to 64 years) per 100,000 member months ³	1,450,781	274	18.9	16.7	21.1	16.0	+	19.4	n.s.	NA
PA EQR	Diabetes Short-Term Complications Admission Rate (Ages 65+ years) per 100,000 member months ³	13,151	1	7.6	0.0	22.5	0.0	n.s.	5.8	n.s.	NA
PA EQR	Diabetes Short-Term Complications Admission Rate (Total Ages 18+ years) per 100,000 member months ³	1,463,932	275	18.8	16.6	21.0	15.9	+	19.3	n.s.	NA
HEDIS	Statin Therapy for Patients With Diabetes: Received Statin Therapy	3,647	2,490	68.3%	66.8%	69.8%	67.5%	n.s.	69.6%	n.s.	>= 50th and < 75th percentile
HEDIS	Statin Therapy for Patients With Diabetes: Statin Adherence 80%	2,490	1,730	69.5%	67.7%	71.3%	58.6%	+	73.8%	-	>= 50th and < 75th percentile
PA EQR	Diabetes Care for People with Serious Mental Illness: Hemoglobin A1c (HbA1c) Poor Control (> 9.0%) (Ages 18–64 Years)	710	660	93.0%	91.0%	94.9%	91.9%	n.s.	82.5%	+	NA
PA EQR	Diabetes Care for People with Serious Mental Illness: Hemoglobin A1c (HbA1c) Poor Control (> 9.0%) (Ages 65–75 Years)	4	4	N/A	N/A	N/A	N/A	N/A	78.1%	N/A	NA
HEDIS	Kidney Health Evaluation for Patients with Diabetes (Ages 18 - 64 years)	6,975	2,525	36.2%	35.1%	37.3%	N/A	N/A	38.6%	-	>= 90th percentile

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Kidney Health Evaluation for Patients with Diabetes (Ages 65 - 74 years)	149	69	46.3%	38.0%	54.7%	N/A	N/A	45.4%	n.s.	>= 90th percentile
HEDIS	Kidney Health Evaluation for Patients with Diabetes (Ages 75 - 85 years)	53	15	28.3%	15.2%	41.4%	N/A	N/A	40.5%	n.s.	>= 90th percentile
HEDIS	Kidney Health Evaluation for Patients with Diabetes (Total)	7,177	2,609	36.4%	35.2%	37.5%	N/A	N/A	38.7%	-	>= 90th percentile

¹ For comparison of MY 2020 rates to MY 2019 rates, statistically significant increases are indicated by “+,” statistically significant decreases by “-,” and no statistically significant change by “n.s.” For comparison of MY 2020 rates to MMC rates, the “+” denotes that the plan rate exceeds the MMC rate, the “-” denotes that the MMC rate exceeds the plan rate, and “n.s.” denotes no statistically significant difference between the two rates.

² For HbA1c Poor Control, lower rates indicate better performance.

³ For the Adult Admission Rate measures, lower rates indicate better performance.

Denom: denominator; Num: numerator; MY: measurement year; MMC: Medicaid Managed Care; HEDIS: Healthcare Effectiveness Data and Information Set; PA: Pennsylvania; EQR: external quality review; NA: not available, as no HEDIS percentile is available to compare; 2021 Rate N/A: not applicable, as denominator is less than 30; N/A: not applicable.

Cardiovascular Care

No strengths are identified for the Cardiovascular Care performance measures.

Opportunities for improvement are identified for the following Cardiovascular Care performance measures:

- The following rates are statistically significantly below/worse than the 2021 (MY 2020) MMC weighted average:
 - Heart Failure Admission Rate (Age 18-64 years) per 100,000 member months – 4.90 admissions per 100,000 member months;
 - Heart Failure Admission Rate (Age 65+ years) per 100,000 member months – 71.07 admissions per 100,000 member months; and
 - Heart Failure Admission Rate (Total Age 18+ years) per 100,000 member months – 5.53 admissions per 100,000 member months.

Table 2.10: Cardiovascular Care

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Persistence of Beta Blocker Treatment After Heart Attack	111	94	84.7%	77.5%	91.8%	67.9%	+	85.9%	n.s.	>= 50th and < 75th percentile

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Controlling High Blood Pressure (Total Rate)	411	258	62.8%	58.0%	67.6%	69.1%	n.s.	63.4%	n.s.	>= 75th and < 90th percentile
PA EQR	Heart Failure Admission Rate (Ages 18–64 years) per 100,000 member months ²	1,450,781	362	25.0	22.4	27.5	20.3	n.s.	20.0	+	NA
PA EQR	Heart Failure Admission Rate (Ages 65+ years) per 100,000 member months ²	13,151	19	144.5	79.5	209.4	56.6	+	73.4	+	NA
PA EQR	Heart Failure Admission Rate (Total Ages 18+ years) per 100,000 member months ²	1,463,932	381	26.0	23.4	28.6	20.6	n.s.	20.5	+	NA
HEDIS	Statin Therapy for Patients With Cardiovascular Disease: Received Statin Therapy 21–75 years (Male)	593	497	83.8%	80.8%	86.9%	80.4%	n.s.	84.7%	n.s.	>= 50th and < 75th percentile
HEDIS	Statin Therapy for Patients With Cardiovascular Disease: Received Statin Therapy 40–75 years (Female)	411	340	82.7%	79.0%	86.5%	80.0%	n.s.	81.8%	n.s.	>= 75th and < 90th percentile
HEDIS	Statin Therapy for Patients With Cardiovascular Disease: Received Statin Therapy Total Rate	1,004	837	83.4%	81.0%	85.7%	80.2%	n.s.	83.5%	n.s.	>= 75th and < 90th percentile
HEDIS	Statin Therapy for Patients With Cardiovascular Disease: Statin Adherence 80%—21–75 years (Male)	497	366	73.6%	69.7%	77.6%	57.7%	+	76.3%	n.s.	>= 50th and < 75th percentile
HEDIS	Statin Therapy for Patients With Cardiovascular Disease: Statin Adherence 80%—40–75 years (Female)	340	241	70.9%	65.9%	75.9%	58.8%	+	76.4%	n.s.	>= 25th and < 50th percentile
HEDIS	Statin Therapy for Patients With Cardiovascular Disease: Statin Adherence 80%—Total Rate	837	607	72.5%	69.4%	75.6%	58.1%	+	76.3%	n.s.	>= 50th and < 75th percentile

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia 18-64 years	21	10	N/A	N/A	N/A	N/A	N/A	73.0%	NA	< 10th percentile
HEDIS	Cardiac Rehabilitation Initiation: ≥ 2 Visits in 30 days (Ages 18 - 64 years)	414	6	1.5%	0.2%	2.7%	N/A	N/A	2.0%	n.s.	≥ 90th percentile
HEDIS	Cardiac Rehabilitation Initiation: ≥ 2 Visits in 30 days (Ages 65 + years)	4	0	N/A	N/A	N/A	N/A	N/A	N/A	NA	NA
HEDIS	Cardiac Rehabilitation Initiation: ≥ 2 Visits in 30 days (Total)	418	6	1.4%	0.2%	2.7%	N/A	N/A	2.0%	n.s.	≥ 90th percentile
HEDIS	Cardiac Rehabilitation Engagement 1: ≥ 12 Visits in 90 days (Ages 18 - 64 years)	414	12	2.9%	1.2%	4.6%	N/A	N/A	2.7%	n.s.	≥ 90th percentile
HEDIS	Cardiac Rehabilitation Engagement 1: ≥ 12 Visits in 90 days (Ages 65 + years)	4	0	N/A	N/A	N/A	N/A	N/A	N/A	NA	NA
HEDIS	Cardiac Rehabilitation Engagement 1: ≥ 12 Visits in 90 days (Total)	418	12	2.9%	1.1%	4.6%	N/A	N/A	2.7%	n.s.	≥ 90th percentile
HEDIS	Cardiac Rehabilitation Engagement 2: ≥ 24 Visits in 180 days (Ages 18 - 64 years)	414	9	2.2%	0.6%	3.7%	N/A	N/A	2.4%	n.s.	≥ 90th percentile
HEDIS	Cardiac Rehabilitation Engagement 2: ≥ 24 Visits in 180 days (Ages 65 + years)	4	0	N/A	N/A	N/A	N/A	N/A	N/A	NA	NA
HEDIS	Cardiac Rehabilitation Engagement 2: ≥ 24 Visits in 180 days (Total)	418	9	2.2%	0.6%	3.7%	N/A	N/A	2.3%	n.s.	≥ 90th percentile
HEDIS	Cardiac Rehabilitation Achievement: ≥ 36 Visits in 180 days (Ages 18 - 64 years)	414	1	0.2%	0.0%	0.8%	N/A	N/A	1.1%	n.s.	≥ 90th percentile
HEDIS	Cardiac Rehabilitation Achievement: ≥ 36 Visits in 180 days (Ages 65 + years)	4	0	N/A	N/A	N/A	N/A	N/A	N/A	NA	NA

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Cardiac Rehabilitation Achievement: ≥ 36 Visits in 180 days (Total)	418	1	0.2%	0.0%	0.8%	N/A	N/A	1.1%	n.s.	≥ 90th percentile

¹ For comparison of MY 2020 rates to MY 2019 rates, statistically significant increases are indicated by “+,” statistically significant decreases by “-,” and no statistically significant change by “n.s.” For comparison of MY 2020 rates to MMC rates, the “+” denotes that the plan rate exceeds the MMC rate, the “-” denotes that the MMC rate exceeds the plan rate, and “n.s.” denotes no statistically significant difference between the two rates.

² For the Adult Admission Rate measures, lower rates indicate better performance.

Denom: denominator; Num: numerator; MY: measurement year; MMC: Medicaid Managed Care; HEDIS: Healthcare Effectiveness Data and Information Set; PA: Pennsylvania; EQR: external quality review; NA: not available, as no HEDIS percentile is available to compare; 2021 Rate N/A: not applicable, as denominator is less than 30; N/A: not applicable.

Utilization

Strengths are identified for the following Utilization performance measures:

- The following rates are statistically significantly above/better than the 2021 (MY 2020) MMC weighted average:
 - Concurrent Use of Opioids and Benzodiazepines (Total Age 18 years and older) – 5.7 percentage points.

Opportunities for improvement are identified for the following Utilization measures:

- The following rates are statistically significantly below/worse than the 2021 (MY 2020) MMC weighted average:
 - Adherence to Antipsychotic Medications for Individuals with Schizophrenia – 9.1 percentage points;
 - Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose Testing (Age 12-17 years) – 8.0 percentage points;
 - Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose Testing (Total Age 1-17 years) – 5.7 percentage points;
 - Metabolic Monitoring for Children and Adolescents on Antipsychotics: Cholesterol Testing (Age 12-17 years) – 8.4 percentage points;
 - Metabolic Monitoring for Children and Adolescents on Antipsychotics: Cholesterol Testing (Total Age 1-17 years) – 5.8 percentage points;
 - Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose & Cholesterol Testing (Age 12-17 years) – 7.9 percentage points; and
 - Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose & Cholesterol Testing (Total Age 1-17 years) – 5.6 percentage points.

Table 2.11: Utilization

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Adherence to Antipsychotic Medications for Individuals with Schizophrenia	605	339	56.0%	52.0%	60.1%	55.9%	n.s.	65.1%	-	≥ 10th and < 25th percentile

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
PA EQR	Adherence to Antipsychotic Medications for Individuals with Schizophrenia (BH Enhanced)	1,203	806	67.0%	64.3%	69.7%	70.0%	n.s.	68.1%	n.s.	NA
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose Testing (Ages 1-11 years)	255	165	64.7%	58.6%	70.8%	74.0%	-	65.4%	n.s.	>= 90th percentile
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose Testing (Ages 12-17 years)	642	410	63.9%	60.1%	67.7%	75.0%	-	71.9%	-	>= 90th percentile
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose Testing (Total Ages 1-17 years)	897	575	64.1%	60.9%	67.3%	74.7%	-	69.8%	-	>= 90th percentile
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Cholesterol Testing (Ages 1-11 years)	255	160	62.8%	56.6%	68.9%	70.5%	n.s.	61.7%	n.s.	>= 90th percentile
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Cholesterol Testing (Ages 12-17 years)	642	333	51.9%	47.9%	55.8%	63.1%	-	60.3%	-	>= 90th percentile
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Cholesterol Testing (Total Ages 1-17 years)	897	493	55.0%	51.6%	58.3%	65.3%	-	60.7%	-	>= 90th percentile
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose & Cholesterol Testing (Ages 1-11 years)	255	149	58.4%	52.2%	64.7%	67.4%	-	58.4%	n.s.	>= 90th percentile
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose & Cholesterol Testing (Ages 12-17 years)	642	323	50.3%	46.4%	54.3%	62.0%	-	58.2%	-	>= 90th percentile

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose & Cholesterol Testing (Total Ages 1-17 years)	897	472	52.6%	49.3%	55.9%	63.6%	-	58.2%	-	>= 90th percentile
HEDIS	Use of Opioids at High Dosage ²	1,262	117	9.3%	7.6%	10.9%	11.1%	n.s.	8.6%	n.s.	>= 25th and < 50th percentile
HEDIS	Use of Opioids From Multiple Providers (4 or more prescribers) ³	1,666	271	16.3%	14.5%	18.1%	14.6%	n.s.	13.6%	+	>= 50th and < 75th percentile
HEDIS	Use of Opioids From Multiple Providers (4 or more pharmacies) ³	1,666	24	1.4%	0.8%	2.0%	2.4%	-	1.4%	n.s.	>= 75th and < 90th percentile
HEDIS	Use of Opioids From Multiple Providers (4 or more prescribers & pharmacies) ³	1,666	12	0.7%	0.3%	1.2%	1.1%	n.s.	0.7%	n.s.	>= 75th and < 90th percentile
HEDIS	Risk of Continued Opioid Use - At Least 15 Days (Ages 18 - 64 years) ⁴	8,178	262	3.2%	2.8%	3.6%	4.6%	-	5.1%	-	>= 75th and < 90th percentile
HEDIS	Risk of Continued Opioid Use - At Least 15 Days (Ages 65+ years) ⁴	40	0	0.0%	0.0%	1.3%	N/A	n.s.	6.4%	n.s.	NA
HEDIS	Risk of Continued Opioid Use - At Least 15 Days (Ages 18 years and older) ⁴	8,218	262	3.2%	2.8%	3.6%	4.6%	-	5.1%	-	>= 75th and < 90th percentile
HEDIS	Risk of Continued Opioid Use - At Least 31 Days (Ages 18 - 64 years) ⁴	8,178	189	2.3%	2.0%	2.6%	3.2%	-	3.2%	-	>= 75th and < 90th percentile
HEDIS	Risk of Continued Opioid Use - At Least 31 Days (Ages 65+ years) ⁴	40	0	0.0%	0.0%	1.3%	N/A	n.s.	3.5%	n.s.	NA
HEDIS	Risk of Continued Opioid Use - At Least 31 Days (Ages 18 years and older) ⁴	8,218	189	2.3%	2.0%	2.6%	3.2%	-	3.2%	-	>= 75th and < 90th percentile
PA EQR	Concurrent Use of Opioids and Benzodiazepines (Ages 18-64 years) ⁵	1,340	173	12.9%	11.1%	14.7%	15.2%	n.s.	18.6%	-	NA
PA EQR	Concurrent Use of Opioids and Benzodiazepines (Ages 65 years and older) ⁵	1	0	N/A	N/A	N/A	N/A	N/A	9.6%	N/A	NA
PA EQR	Concurrent Use of Opioids and Benzodiazepines (Total Ages 18 years and older) ⁵	1,341	173	12.9%	11.1%	14.7%	15.2%	n.s.	18.6%	-	NA

		2021 (MY 2020)					2021 (MY 2020) Rate Comparison ¹				
Indicator Source	Indicator	Denom	Num	Rate	Lower 95% Confidence Interval	Upper 95% Confidence Interval	2020 (MY 2019) Rate	2021 Rate Compared to 2020	MMC	2021 Rate Compared to MMC	HEDIS 2021 Percentile
HEDIS	Pharmacotherapy for Opioid Use Disorder (Ages 16-64 years)	2,025	506	25.0%	23.1%	26.9%	22.5%	n.s.	27.2%	-	>= 25th and < 50th percentile
HEDIS	Pharmacotherapy for Opioid Use Disorder (Ages 65+ years)	8	1	N/A	N/A	N/A	N/A	N/A	N/A	N/A	< 10th percentile
HEDIS	Pharmacotherapy for Opioid Use Disorder (Total Ages 16+ years)	2,033	507	24.9%	23.0%	26.8%	22.6%	n.s.	27.2%	n.s.	>= 25th and < 50th percentile
PA EQR	Use of Pharmacotherapy for Opioid Use Disorder (Total)	576	451	78.3%	74.8%	81.8%	71.5%	+	75.2%	n.s.	NA
PA EQR	Use of Pharmacotherapy for Opioid Use Disorder (Buprenorphine)	576	423	73.4%	69.7%	77.1%	64.6%	+	69.3%	n.s.	NA
PA EQR	Use of Pharmacotherapy for Opioid Use Disorder (Oral Naltrexone)	576	27	4.7%	2.9%	6.5%	3.9%	n.s.	4.0%	n.s.	NA
PA EQR	Use of Pharmacotherapy for Opioid Use Disorder (Long-Acting, Injectable Naltrexone)	576	46	8.0%	5.7%	10.3%	7.9%	n.s.	7.0%	n.s.	NA
PA EQR	Use of Pharmacotherapy for Opioid Use Disorder (Methadone)	576	4	0.7%	0.0%	1.5%	1.0%	n.s.	2.5%	-	NA

¹ For comparison of MY 2020 rates to MY 2019 rates, statistically significant increases are indicated by “+,” statistically significant decreases by “-,” and no statistically significant change by “n.s.” For comparison of MY 2020 rates to MMC rates, the “+” denotes that the plan rate exceeds the MMC rate, the “-” denotes that the MMC rate exceeds the plan rate, and “n.s.” denotes no statistically significant difference between the two rates.

² For the Use of Opioids at High Dosage measure, lower rates indicate better performance.

³ For the Use of Opioids From Multiple Providers measure, lower rates indicate better performance.

⁴ For the Risk of Continued Opioid Use measure, lower rates indicate better performance.

⁵ For the Concurrent Use of Opioids and Benzodiazepines measure, lower rates indicate better performance.

Denom: denominator; Num: numerator; MY: measurement year; MMC: Medicaid Managed Care; HEDIS: Healthcare Effectiveness Data and Information Set; PA: Pennsylvania; EQR: external quality review; NA: not available, as no HEDIS percentile is available to compare; 2021 Rate N/A: not applicable, as denominator is less than 30; N/A: not applicable.

Table 2.12: Utilization (Continued)

Indicator Source	Indicator ²	2021 (MY 2020)		2021 (MY 2020) Rate Comparison ¹		
		Count	Rate	2020 (MY 2019) Rate	2021 Rate Compared to 2020	HEDIS 2021 Percentile
HEDIS	Plan All-Cause Readmissions: Count of Index Hospital Stays (IHS)—Total Stays (Ages Total)	5,499		5,000		NA
HEDIS	Plan All-Cause Readmissions: Count of 30-Day Readmissions—Total Stays (Ages Total)	599		509		NA
HEDIS	Plan All-Cause Readmissions: Observed Readmission Rate—Total Stays (Ages Total)		10.9%	10.2%	N/A	NA
HEDIS	Plan All-Cause Readmissions: Expected Readmission Rate—Total Stays (Ages Total)		9.7%	9.8%	N/A	NA
HEDIS	Plan All-Cause Readmissions: Observed to Expected Readmission Ratio—Total Stays (Ages Total)		1.1	1.0	N/A	NA

¹ For comparison of MY 2020 rates to MY 2019 rates, statistically significant increases are indicated by “+,” statistically significant decreases by “-,” and no statistically significant change by “n.s.” For comparison of MY 2020 rates to MMC rates, the “+” denotes that the plan rate exceeds the MMC rate, the “-” denotes that the MMC rate exceeds the plan rate, and “n.s.” denotes no statistically significant difference between the two rates.

² For the Plan All-Cause Readmissions (PCR) measure, cells that are grey shaded are data elements that are not relevant to the measure.

MY: measurement year; HEDIS: Healthcare Effectiveness Data and Information Set; NA: not available, as no HEDIS percentile is available to compare; N/A: not applicable.

Consumer Assessment of Healthcare Providers and Systems (CAHPS) Survey

Satisfaction with the Experience of Care

Table 2.13 and **Table 2.14** provide the survey results of four composite questions by two specific categories for UHC across the last 3 measurement years, as available. The composite questions target the MCO's performance strengths as well as opportunities for improvement.

Due to differences in the CAHPS submissions from year to year, direct comparisons of results are not always available. Questions that are not included in the most recent survey version are not presented in **Table 2.13** and **Table 2.14**.

MY 2020 Adult CAHPS 5.1H Survey Results

Table 2.13: CAHPS MY 2020 Adult Survey Results

Survey Section/Measure	2021 (MY 2020)	2021 Rate Compared to 2020	2020 (MY 2019)	2020 Rate Compared to 2019	2019 (MY 2018)	2021 MMC Weighted Average
Your Health Plan						
Satisfaction with Adult's Health Plan (Rating of 8–10)	78.24%	▼	81.98%	▲	79.31%	81.40%
Getting Needed Information (Usually or Always)	85.57%	▲	85.11%	▲	78.31%	84.68%
Your Health Care in the Last 6 Months						
Satisfaction with Health Care (Rating of 8–10)	81.03%	▲	73.53%	▼	75.00%	79.53%
Appointment for Routine Care When Needed (Usually or Always)	78.92%	▼	81.37%	▲	76.44%	82.26%

▲ ▼ = Performance increased (▲) or decreased (▼) compared to prior year's rate.

Gray shaded boxes reflect rates above the MY 2020 MMC Weighted Average.

CAHPS: Consumer Assessment of Healthcare Providers and Systems; MY: measurement year; MMC: Medicaid managed care.

MY 2020 Child CAHPS 5.1H Survey Results

Table 2.14: CAHPS MY 2020 Child Survey Results

Survey Section/Measure	2021 (MY 2020)	2021 Rate Compared to 2020	2020 (MY 2019)	2020 Rate Compared to 2019	2019 (MY 2018)	2021 MMC Weighted Average
Your Child's Health Plan						
Satisfaction with Child's Health Plan (Rating of 8–10)	85.99%	▼	86.50%	▲	83.37%	88.71%
Information or Help from Customer Service (Usually or Always)	79.55%	▼	81.43%	▼	84.85%	81.29%
Your Healthcare in the Last 6 Months						
Satisfaction with Health Care (Rating of 8–10)	88.83%	▼	89.74%	▲	85.17%	88.84%
Appointment for Routine Care When Needed (Usually or Always)	83.42%	▼	88.78%	▲	87.65%	84.77%

▲ ▼ = Performance compared to prior year's rate.

CAHPS: Consumer Assessment of Healthcare Providers and Systems; MY: measurement year; MMC: Medicaid managed care.

III: Review of Compliance with Medicaid and CHIP Managed Care Regulations

Objectives

This section of the EQR report presents a review by IPRO of United Healthcare's (UHC's) compliance with its contract and with state and federal regulations. The review is based on information derived from reviews of the MCO that were conducted by PA DHS within the past three years, most typically within the immediately preceding year.

The SMART items are a comprehensive set of monitoring items that have been developed by PA DHS from the managed care regulations. PA DHS staff reviews SMART items on an ongoing basis for each Medicaid MCO. These items vary in review periodicity as determined by DHS and reviews typically occur annually or as needed. Additionally, reviewers have the option to review individual zones covered by an MCO separately, and to provide multiple findings within a year (e.g., quarterly). Within the SMART system there is a mechanism to include review details, where comments can be added to explain the MCO's compliance, partial compliance, or non-compliance. There is a year allotted to complete all of the SMART standards; if an MCO is non-compliant or partially compliant, this time is built into the system to prevent a Standard from being "finalized." If an MCO does not address a compliance issue, DHS would discuss as a next step the option to issue a Work Plan, a Performance Improvement Plan, or a Corrective Action Plan (CAP). Any of these next steps would be communicated via formal email communications with the MCO. Per DHS, MCOs usually address the issues in SMART without the necessity for any of these actions, based on the SMART timeline.

Description of Data Obtained

The documents used by IPRO for the current review include the HealthChoices Agreement, the SMART database completed by PA DHS staff as of December 31, 2020, additional monitoring activities outlined by DHS staff, and the most recent NCQA Accreditation Survey for UHC effective in the review year.

The SMART items provided much of the information necessary for this review. The SMART items and their associated review findings for each year are maintained in a database. The SMART database has been maintained internally at DHS since Review Year (RY) 2013. Beginning in 2018 (RY 2017), there were changes implemented to the review process that impacted the data that are received annually. First, the only available review conclusions are Compliant and non-Compliant. All other options previously available were re-designated from review conclusion elements to review status elements and are therefore not included in the findings. Additionally, as noted, reviewers were given the option to review zones covered by an MCO separately, and to provide multiple findings within a year (e.g., quarterly). As a result, there was an increase in the number of partially compliant items for the initial year. For use in the current review, IPRO reviewed the data elements from each version of database and then merged the RY 2019, 2018, and 2017 findings. IPRO reviewed the elements in the SMART item list and created a crosswalk to pertinent BBA regulations. A total of 135 items were identified that were relevant to evaluation of MCO compliance with the BBA regulations.

The crosswalk linked SMART Items to specific provisions of the regulations, where possible. Some items were relevant to more than one provision. The most recently revised CMS protocols included updates to the structure and compliance standards, including which standards are required for compliance review. Under these protocols, there are 11 standards that CMS has designated as required to be subject to compliance review. Several previously required standards have been deemed by CMS as incorporated into the compliance review through interaction with the new required standards, and appear to assess items that are related to the required standards. The compliance evaluation was conducted on the crosswalked regulations for all 11 required standards and remaining related standards that were previously required and continue to be reviewed.

Table 3.1 provides a count of items linked to each category. Additionally, **Table 3.1** includes all regulations and standards from the three year review period (RY 2020, 2019, and 2018), which incorporates both the prior and the most recent set of EQR protocols. The CMS regulations are reflected in **Table 3.1** as follows: 1) a *Required* column has been included to indicate the 11 standards that CMS has designated as subject to compliance review, and 2) a *Related* column has been included to indicate standards that CMS has deemed as incorporated into the compliance review through interaction with the required standards.

Table 3.1: SMART Items Count per Regulation

BBA Regulation	SMART Items	Required	Related
Subpart C: Enrollee Rights and Protections			
Enrollee Rights	7		✓
Provider-Enrollee Communication	1		✓
Marketing Activities	2		✓
Liability for Payment	1		
Cost Sharing	0		
Emergency and Post-Stabilization Services – Definition	4		✓
Emergency Services: Coverage and Payment	1		✓
Solvency Standards	2		
Subpart D: MCO, PIHP and PAHP Standards			
Availability of Services	14	✓	
Assurances of adequate capacity and services	3	✓	
Coordination and Continuity of Care	13	✓	
Coverage and Authorization of Services	9	✓	
Provider Selection	4	✓	
Provider Discrimination Prohibited	1		✓
Confidentiality	1	✓	
Enrollment and Disenrollment	2		✓
Grievance and appeal Systems	1	✓	
Subcontractual Relationships and Delegations	3	✓	
Practice Guidelines	2	✓	
Health Information Systems	18	✓	
Subpart E: Quality Measurement and Improvement; External Quality Review			
Quality assessment and performance improvement program (QAPI)	9	✓	
Subpart F: Grievance and Appeal System			
General Requirements	8		✓
Notice of Action	3		✓
Handling of Grievances and Appeals	9		✓
Resolution and Notification	7		✓
Expedited Resolution	4		✓
Information to Providers and Subcontractors	1		✓
Recordkeeping and Recording	6		✓
Continuation of Benefits Pending Appeal and State Fair Hearings	2		✓
Effectuation of Reversed Resolutions	0		✓

Two previous categories, Cost Sharing and Effectuation of Reversed Resolutions, were not directly addressed by any of the SMART Items reviewed by DHS. Cost Sharing is addressed in the HealthChoices Agreement. Effectuation of Reversed Resolutions is evaluated as part of the most recent NCQA Accreditation review under Utilization Management (UM) Standard 8: Policies for Appeals and UM 9: Appropriate Handling of Appeals.

Review of Assurances of adequate capacity and services included three additional SMART Items that reference requirements related to provider agreements and reporting of appropriate services. Additionally, monitoring team review activities addressed other elements as applicable, including: readiness reviews of a new MCO’s network against the requirements in the HealthChoices Agreement to ensure the ability to adequately serve the potential membership

2021 External Quality Review Report: United Healthcare Page 56 of 76

population; review of provider networks on several levels, such as annual MCO submissions of provider network, weekly submissions of provider additions/deletions together with executive summaries of gaps and plans of action to fill gaps as required, and regular monitoring of adequacy through review and approval of provider directories, access to care campaigns and as needed; periodic review of provider terminations with potential to cause gaps in the MCO provider network, as well as review with the MCO of the provider termination process outlined in the HealthChoices Agreement.

Determination of Compliance

To evaluate MCO compliance on individual provisions, IPRO grouped the monitoring standards by provision and evaluated the MCO's compliance status with regard to the SMART Items. For example, all provisions relating to availability of services are summarized under Availability of Services §438.206. This grouping process was done by referring to CMS's "Regulations Subject to Compliance Review", where specific Medicaid regulations are noted as required for review and corresponding sections are identified and described for each Subpart, particularly D and E. Each item was assigned a value of Compliant or non-Compliant in the Item Log submitted by DHS. If an item was not evaluated for a particular MCO, it was assigned a value of Not Determined. Compliance with the BBA requirements was then determined based on the aggregate results of the SMART Items linked to each provision within a requirement or category. If all items were Compliant, the MCO was evaluated as Compliant. If some were Compliant and some were non-Compliant, the MCO was evaluated as partially-Compliant. If all items were non-Compliant, the MCO was evaluated as non-Compliant. If no items were evaluated for a given category and no other source of information was available to determine compliance, a value of Not Determined was assigned for that category.

Categories determined to be partially- or non-Compliant are indicated where applicable in the tables below, and the SMART Items that were assigned a value of non-Compliant by DHS within those categories are noted. For UHC, there were no categories determined to be partially- or non-Compliant, signifying that no SMART Items were assigned a value of non-Compliant by DHS. **There are therefore no recommendations related to compliance with structure and operations standards for UHC for the current review year.**

In addition to this analysis of DHS's monitoring of MCO compliance with managed care regulations, IPRO reviewed and evaluated the most recent NCQA accreditation report for each MCO. IPRO accessed the NCQA *Health Plan Reports* website¹ to review the *Health Plan Report Cards 2021* for UHC. For each MCO, star ratings, accreditation status, plan type, and distinctions were displayed. At the MCO-specific pages, information displayed was related to membership size, accreditation status, survey type and schedule, and star ratings for each measure and overall.

Format

The format for this section of the report was developed to be consistent with the subparts prescribed by BBA regulations. This document groups the regulatory requirements under subject headings that are consistent with the subparts set out in the BBA regulations and described in the CMS EQR Protocol: *Review of Compliance with Medicaid and CHIP Managed Care Regulations*. Under each subpart heading fall the individual regulatory categories appropriate to those headings. Findings will be further discussed relative to applicable subparts as indicated in the updated Protocol, i.e., Subpart D – MCO, PIHP and PAHP Standards and Subpart E – Quality Measurement and Improvement.

This format reflects the goal of the review, which is to gather sufficient foundation for IPRO's required assessment of the MCO's compliance with BBA regulations as an element of the analysis of the MCO's strengths and weaknesses.

¹ NCQA *Health Plan Report Cards* Website: <https://reportcards.ncqa.org/health-plans>. Accessed January 25, 2022.

Findings

Of the 135 SMART Items, 74 items were evaluated and 61 were not evaluated for the MCO in RY 2020, RY 2019, or RY 2018. For categories where items were not evaluated for compliance for RY 2020, results from reviews conducted within the two prior years (RY 2019 and RY 2018) were evaluated to determine compliance, if available.

Subpart C: Enrollee Rights and Protections

The general purpose of the regulations included in this category is to ensure that each MCO had written policies regarding enrollee rights and complies with applicable Federal and State laws that pertain to enrollee rights, and that the MCO ensures that its staff and affiliated providers take into account those rights when furnishing services to enrollees. [42 C.F.R. §438.100 (a), (b)].

The SMART database and DHS’s audit document information include assessment of the MCO’s compliance with regulations found in Subpart C. **Table 3.2** presents the findings by categories consistent with the regulations. As indicated in **Table 3.1**, no regulation in this subpart is included in the updated required standards, although several are related standards.

Table 3.2: UHC Compliance with Enrollee Rights and Protections Regulations

ENROLLEE RIGHTS AND PROTECTIONS REGULATIONS		
Subpart C: Categories	Compliance	Comments
Enrollee Rights	Compliant	7 items were crosswalked to this category. The MCO was evaluated against 6 items and was compliant on 6 items based on RY 2020.
Provider-Enrollee Communication	Compliant	1 item was crosswalked to this category. The MCO was evaluated against 1 item and was compliant on this item based on RY 2020.
Marketing Activities	Compliant	2 items were crosswalked to this category. The MCO was evaluated against 1 item and was compliant on 1 item based on RY 2020.
Cost Sharing	Compliant	Per HealthChoices Agreement
Emergency Services: Coverage and Payment	Compliant	1 item was crosswalked to this category. The MCO was evaluated against 1 item and was compliant on this item based on RY 2020.
Emergency and Post Stabilization Services	Compliant	4 items were crosswalked to this category. The MCO was evaluated against 3 items and was compliant on 3 items based on RY 2020.

MCO: managed care organization; RY: reporting year.

UHC was evaluated against 15 of the 18 SMART Items crosswalked to Enrollee Rights and Protections Regulations and was compliant on all 15 items. UHC was found to be compliant on all eight of the categories of Enrollee Rights and Protections Regulations. UHC was found to be compliant on the Cost Sharing provision, based on the HealthChoices Agreement.

Subpart D: MCO, PIHP and PAHP Standards

The general purpose of the regulations included under this heading is to ensure that all services available under the commonwealth’s Medicaid managed care program are available and accessible to UHC enrollees. [42 C.F.R. §438.206 (a)].

The SMART database includes an assessment of the MCO’s compliance with regulations found in Subpart D. For the category of Assurances of Adequate Capacity and Services, the MCO was evaluated as noted above against additional SMART Items and DHS monitoring activities. **Table 3.3** presents the findings by categories consistent with the regulations. Regulations that have been designated in **Table 3.1** as required under the updated protocols are **bolded**. The remaining are related standards.

Table 3.3: UHC Compliance with MCO, PIHP and PAHP Standards Regulations

MCO, PIHP AND PAHP STANDARDS REGULATIONS		
Subpart D: Categories	Compliance	Comments
Availability of Services	Compliant	14 items were crosswalked to this category. The MCO was evaluated against 10 items and was compliant on 10 items based on RY 2020.
Assurances of Adequate Capacity and Services	Compliant	3 items were crosswalked to this category. This category was evaluated against SMART Items and RY 2019 DHS monitoring activities.
Coordination and Continuity of Care	Compliant	13 items were crosswalked to this category. The MCO was evaluated against 12 items and was compliant on 12 items based on RY 2020.
Coverage and Authorization of Services	Compliant	9 items were crosswalked to this category. The MCO was evaluated against 7 items and was compliant on 7 items based on RY 2020.
Provider Selection	Compliant	4 items were crosswalked to this category. The MCO was evaluated against 1 item and was compliant on this item based on RY 2020.
Provider Discrimination Prohibited	Compliant	1 item was crosswalked to this category. The MCO was evaluated against 1 item and was compliant on this item based on RY 2020.
Confidentiality	Compliant	1 item was crosswalked to this category. The MCO was evaluated against 1 item and was compliant on this item based on RY 2020.
Enrollment and Disenrollment	Compliant	2 items were crosswalked to this category. The MCO was evaluated against 1 item and was compliant on this item based on RY 2020.
Grievance and Appeal Systems	Compliant	1 item was crosswalked to this category. The MCO was evaluated against 1 item and was compliant on this item based on RY 2020.
Subcontractual Relationships and Delegations	Compliant	3 items were crosswalked to this category. The MCO was evaluated against 3 items and was compliant on 3 items based on RY 2020.
Practice Guidelines	Compliant	2 items were crosswalked to this category. The MCO was evaluated against 1 item and was compliant on 1 item based on RY 2020.
Health Information Systems	Compliant	18 items were crosswalked to this category. The MCO was evaluated against 10 items and was compliant on 10 items based on RY 2020.

MCO: managed care organization; PIHP: prepaid inpatient health plan; PAHP: prepaid ambulatory health plan; RY: reporting year.

UHC was evaluated against 48 of 71 SMART Items that were crosswalked to MCO, PIHP and PAHP Standards Regulations and was compliant on all 48 items. Of the 12 categories in MCO, PIHP and PAHP Standards, UHC was found to be compliant on all 12 categories.

Subpart E: Quality Measurement and Improvement; External Quality Review

The general purpose of the regulations included under this heading is to ensure that managed care entities establish and implement an ongoing comprehensive QAPI program for the services it furnishes to its Medicaid enrollees. [42 C.F.R. §438.330].

The MCO’s compliance with the regulation found in Subpart E was evaluated as noted above against additional SMART Items and DHS monitoring activities. **Table 3.4** presents the findings by categories consistent with the regulation. This regulation has been designated in **Table 3.1** as required under the updated protocols and is **bolded**.

Table 3.4: UHC Compliance with Quality Measurement and Improvement; External Quality Review Regulations

QUALITY MEASUREMENT AND IMPROVEMENT; EXTERNAL QUALITY REVIEW REGULATIONS		
Subpart E: Categories	Compliance	Comments
Quality Assessment and Performance Improvement Program (QAPI)	Compliant	9 items were crosswalked to this category. The MCO was evaluated against 1 item and was compliant on this item based on RY 2020.

MCO: managed care organization; RY: reporting year.

UHC was evaluated against one of the nine SMART Items crosswalked to Quality Assessment and Performance Improvement Program (QAPI) and was compliant on the one item.

Subpart F: Grievance and Appeal System

The general purpose of the regulations included under this heading is to ensure that enrollees have the ability to pursue grievances.

The SMART database and DHS’s audit document information include assessment of the MCO’s compliance with regulations found in Subpart F. **Table 3.5** presents the findings by categories consistent with the regulations. As indicated in **Table 3.1**, no regulation in this subpart is included in the updated required standards, although all are related standards.

Table 3.5: UHC Compliance with Grievance and Appeal System Regulations

GRIEVANCE AND APPEAL SYSTEM REGULATIONS		
Subpart F: Categories	Compliance	Comments
General Requirements	Compliant	8 items were crosswalked to this category. The MCO was evaluated against 1 item and was compliant on this item based on RY 2020.
Notice of Action	Compliant	3 items were crosswalked to this category. The MCO was evaluated against 2 items and was compliant on 2 items based on RY 2020.
Handling of Grievances & Appeals	Compliant	9 items were crosswalked to this category. The MCO was evaluated against 2 items and was compliant on 2 items based on RY 2020.
Resolution and Notification	Compliant	7 items were crosswalked to this category. The MCO was evaluated against 2 items and was compliant on 2 items based on RY 2020.
Expedited Resolution	Compliant	4 items were crosswalked to this category. The MCO was evaluated against 2 items and was compliant on 2 items based on RY 2020.
Information to Providers and Subcontractors	Compliant	1 item was crosswalked to this category. The MCO was evaluated against 1 item and was compliant on this item based on RY 2020.

GRIEVANCE AND APPEAL SYSTEM REGULATIONS		
Subpart F: Categories	Compliance	Comments
Recordkeeping and Recording	Compliant	6 items were crosswalked to this category. The MCO was evaluated against 2 items and was compliant on 2 items based on RY 2020.
Continuation of Benefits Pending Appeal and State Fair Hearings	Compliant	2 items were crosswalked to this category. The MCO was evaluated against 1 item and was compliant on this item based on RY 2020.
Effectuation of Reversed Resolutions	Compliant	Per NCQA Accreditation, 2021. (See "Accreditation Status" below)

MCO: managed care organization; RY: reporting year; NCQA: National Committee for Quality Assurance.

UHC was evaluated against 13 of the 40 SMART Items crosswalked to Grievance and Appeal System and was compliant on all 13 items. UHC was found to be compliant for all nine categories of Grievance and Appeal System. For the category of Effectuation of Reversed Resolutions, per the NCQA website, the plan is Accredited. NCQA did not conduct surveys due to the COVID-19 pandemic.

Accreditation Status

UHC underwent an NCQA Accreditation Survey evaluation June 30, 2021 due to COVID-19. It is effective through June 7, 2022 they were granted an Accreditation Status of Accredited.

IV: MCO Responses to the Previous EQR Recommendations

Title 42 CFR § 438.364 External quality review results (a)(6) require each annual technical report include “an assessment of the degree to which each MCO, PIHP, PAHP, or PCCM entity has effectively addressed the recommendations for QI made by the EQRO during the previous year’s EQR.” **Table 4.1** displays the MCO’s opportunities as well as IPRO’s assessment of their responses. The detailed responses are included in the embedded Word document. In addition to the opportunities identified from the EQR, DHS also required MCOs to develop a root cause analysis around select P4P indicators.

Current and Proposed Interventions

The general purpose of this section is to assess the degree to which each PH MCO has addressed the opportunities for improvement made by IPRO in the 2020 EQR Technical Reports, which were distributed May 2021. The 2021 EQR is the thirteenth to include descriptions of current and proposed interventions from each PH MCO that address the prior year reports’ recommendations.

DHS requested that MCOs submit descriptions of current and proposed interventions using the Opportunities for Improvement form developed by IPRO to ensure that responses are reported consistently across the MCOs. These activities follow a longitudinal format, and are designed to capture information relating to:

- Follow-up actions that the MCO has taken through June 30, 2021 to address each recommendation;
- Future actions that are planned to address each recommendation;
- When and how future actions will be accomplished;
- The expected outcome or goals of the actions that were taken or will be taken; and
- The MCO’s process(es) for monitoring the action to determine the effectiveness of the actions taken.

The documents informing the current report include the response submitted to IPRO as of September 2021, as well as any additional relevant documentation provided by UHC.

The embedded Word document presents UHC’s responses to opportunities for improvement cited by IPRO in the 2020 EQR Technical Report, detailing current and proposed interventions.



UHC 2020 Opps
Response Request f

Root Cause Analysis and Action Plan

The 2021 EQR is the twelfth year MCOs were required to prepare a Root Cause Analysis and Action Plan for measures on the HEDIS MY 2020 P4P Measure Matrix receiving either “D” or “F” ratings. Each P4P measure in categories “D” and “F” required that the MCO submit:

- A goal statement;
- Root cause analysis and analysis findings;
- Action plan to address findings;
- Implementation dates; and
- A monitoring plan to assure action is effective and to address what will be measured and how often that measurement will occur.

UHC submitted an initial Root Cause Analysis and Action Plan in September 2021. For each measure in grade categories D and F, UHC completed the embedded form, identifying factors contributing to poor performance.



For the 2021 EQR, UHC was required to prepare a Root Cause Analysis and Action Plan for the following performance measures:

- Medication Management for People with Asthma: 75% Total.

UHC Response to Previous EQR Recommendations

Table 4.1 displays UHC’s progress related to the 2020 External Quality Review Report, as well as IPRO’s assessment of UHC’s response.

Table 1: UHC Response to Previous EQR Recommendations

Recommendation for UHC	IPRO Assessment of MCO Response ¹
Children and Adolescents’ Access to PCPs (Age 25 months-6 years)	Measure retired
Children and Adolescents’ Access to PCPs (Age 7-11 years)	Measure retired
Children and Adolescents’ Access to PCPs (Age 12-19 years)	Measure retired
Adults’ Access to Preventive/Ambulatory Health Services (Age 20-44 years)	Remains and opportunity for improvement
Adults’ Access to Preventive/Ambulatory Health Services (Age 45-64 years)	Remains and opportunity for improvement
Adults’ Access to Preventive/Ambulatory Health Services (Age 65+ years)	Partially addressed
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Ages 12 to 17)	Partially addressed
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Total ages 1 to 17)	Addressed
Lead Screening in Children (Age 2 years)	Addressed
Follow-up Care for Children Prescribed ADHD Medication - Initiation Phase	Partially addressed
Follow-up Care for Children Prescribed ADHD Medication - Continuation Phase	Addressed
Follow-up Care for Children Prescribed ADHD Medication (BH Enhanced) - Initiation Phase	Partially addressed
Follow-up Care for Children Prescribed ADHD Medication (BH Enhanced) - Continuation Phase	Addressed
Developmental Screening in the First Three Years of Life - 3 years	Addressed
Follow-Up After Emergency Department Visit for Mental Illness or Alcohol and Other Drug Abuse or Dependence (Ages: 18 to 64 - ED visits for mental illness, follow-up within 7 days)	Partially addressed
Follow-Up After Emergency Department Visit for Mental Illness or Alcohol and Other Drug Abuse or Dependence (Ages: 18 to 64 - ED visits for mental illness, follow-up within 30 days)	Partially addressed
Annual Dental Visit (Age 2–20 years)	Partially addressed
Annual Dental Visits for Members with Developmental Disabilities (Age 2-20years)	Remains and opportunity for improvement
Dental Sealants for 6-9 Year Old Children At Elevated Caries Risk	Measure retired
Adult Annual Dental Visit ≥ 21 Years (Age 60-64 years)	Partially addressed

Recommendation for UHC	IPRO Assessment of MCO Response ¹
Breast Cancer Screening (Age 50-74 years)	Remains and opportunity for improvement
Cervical Cancer Screening (Age 21-64 years)	Remains and opportunity for improvement
Contraceptive Care for Postpartum Women: Most or moderately effective contraception - 60 days (Ages 15 to 20)	Remains and opportunity for improvement
Pharmacotherapy Management of COPD Exacerbation: Systemic Corticosteroid	Addressed
Medication Management for People with Asthma - 75% Compliance (Age 5-11 years)	Measure retired
Medication Management for People with Asthma - 75% Compliance (Age 12-18 years)	Measure retired
Medication Management for People with Asthma - 75% Compliance (Age 51-64 years)	Measure retired
Medication Management for People with Asthma - 75% Compliance (Total - Age 5-64 years)	Measure retired
Asthma Medication Ratio (5-11 years)	Addressed
Asthma Medication Ratio (12-18 years)	Addressed
Asthma Medication Ratio (19-50 years)	Addressed
Asthma Medication Ratio (Total)	Addressed
Statin Therapy for Patients With Diabetes: Statin Adherence 80%	Partially addressed
Persistence of Beta Blocker Treatment After Heart Attack	Addressed
Statin Therapy for Patients With Cardiovascular Disease: Received Statin Therapy 21-75 years (Male)	Addressed
Statin Therapy for Patients With Cardiovascular Disease: Received Statin Therapy Total Rate	Addressed
Statin Therapy for Patients With Cardiovascular Disease: Statin Adherence 80% - 21-75 years (Male)	Addressed
Statin Therapy for Patients With Cardiovascular Disease: Statin Adherence 80% - 40-75 years (Female)	Addressed
Statin Therapy for Patients With Cardiovascular Disease: Statin Adherence 80% - Total Rate	Addressed
Adherence to Antipsychotic Medications for Individuals with Schizophrenia	Remains and opportunity for improvement
Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose Testing (Ages 12-17 years)	Remains and opportunity for improvement
Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose Testing (Total Ages 1-17 years)	Remains and opportunity for improvement
Metabolic Monitoring for Children and Adolescents on Antipsychotics: Cholesterol Testing (Ages 12-17 years)	Remains and opportunity for improvement
Metabolic Monitoring for Children and Adolescents on Antipsychotics: Cholesterol Testing (Total Ages 1-17 years)	Remains and opportunity for improvement
Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose & Cholesterol Testing (Ages 12-17 years)	Remains and opportunity for improvement

Recommendation for UHC	IPRO Assessment of MCO Response ¹
Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose & Cholesterol Testing (Total Ages 1-17 years)	Remains and opportunity for improvement
Pharmacotherapy for Opioid Use Disorder (Ages 16-64 years)	Partially addressed
Pharmacotherapy for Opioid Use Disorder (Total Ages 16+ years)	Insufficient data to determine an assessment

¹ IPRO assessments are as follows: **addressed:** MCP's quality improvement (QI) response resulted in demonstrated improvement; **partially addressed:** either of the following (1) improvement was observed, but identified as an opportunity for current year; or (2) improvement not observed, but not identified as an opportunity for current year; **remains an opportunity for improvement:** MCP's QI response did not address the recommendation; improvement was not observed or performance declined. EQR: external quality review; MCO: managed care organization.

V: MCO Strengths and Opportunities for Improvement and EQR Recommendations

The review of the MCO's MY 2020 performance for all EQR activities conducted, against Medicaid and CHIP managed care regulations, performance improvement projects and performance measures identified strengths and opportunities for improvement in the quality outcomes, timeliness of, and access to services for Medicaid members served by this MCO. The strengths and opportunities listed below are also outlined within each applicable section above. Each section contains more detail regarding the review and identification of the items.

Strengths

- The MCO's performance was statistically significantly above/better than the MMC weighted average in 2021 (MY 2020) on the following measures:
 - Body Mass Index: Percentile (Age 3 - 11 years);
 - Body Mass Index: Percentile (Age 12-17 years);
 - Body Mass Index: Percentile (Total);
 - Counseling for Nutrition (Age 3-11 years);
 - Counseling for Nutrition (Age 12-17 years);
 - Counseling for Nutrition (Total);
 - Counseling for Physical Activity (Age 3-11 years);
 - Counseling for Physical Activity (Age 12-17 years);
 - Counseling for Physical Activity (Total);
 - Developmental Screening in the First Three Years of Life - 1 year;
 - Sealant Receipt on Permanent First Molars (≥ 1 Molar);
 - Prenatal Screening for Smoking;
 - Prenatal Screening for Smoking during one of the first two visits (CHIPRA indicator);
 - Prenatal Screening for Environmental Tobacco Smoke Exposure;
 - Prenatal Counseling for Smoking;
 - Prenatal Screening for Depression;
 - Prenatal Screening for Depression during one of the first two visits (CHIPRA indicator);
 - Prenatal Screening Positive for Depression;
 - Postpartum Screening for Depression;
 - Appropriate Testing for Pharyngitis (Age 3-17 years);
 - Appropriate Testing for Pharyngitis (Age 18-64 years);
 - Appropriate Testing for Pharyngitis (Total);
 - Diabetes Care for People with Serious Mental Illness: Hemoglobin A1c (HbA1c) Poor Control ($>9.0\%$) (Age Cohort: 18 - 64 Years of Age); and
 - Use of Pharmacotherapy for Opioid Use Disorder (Total).

- UHC was found to be fully compliant on all contract and with state and federal managed care regulations reviewed.

Opportunities for Improvement

- UHC was found to be partially compliant on all five review elements for the Opioid PIP. UHC was found to be partially compliant on three of five review elements for the Readmissions PIP.

- The MCO's performance was statistically significantly below/worse than the MMC rate in 2021 (MY 2020) as indicated by the following measures:
 - Adults' Access to Preventive/Ambulatory Health Services (Age 20-44 years);
 - Adults' Access to Preventive/Ambulatory Health Services (Age 45-64 years);
 - Follow-up Care for Children Prescribed ADHD Medication - Initiation Phase;
 - Follow-up Care for Children Prescribed ADHD Medication (BH Enhanced) - Initiation Phase;
 - Follow-Up After Emergency Department Visit for Mental Illness or Alcohol and Other Drug Abuse or Dependence (Ages: 18 to 64 - ED visits for mental illness, follow-up within 7 days);
 - Follow-Up After Emergency Department Visit for Mental Illness or Alcohol and Other Drug Abuse or Dependence (Ages: 18 to 64 - ED visits for mental illness, follow-up within 30 days);

- Annual Dental Visits for Members with Developmental Disabilities (Age 2-20 years);
- Breast Cancer Screening (Age 50-74 years);
- Cervical Cancer Screening (Age 21-64 years);
- Contraceptive Care for Postpartum Women: Most or moderately effective contraception - 3 days (Ages 15 to 20);
- Contraceptive Care for Postpartum Women: Most or moderately effective contraception - 60 days (Ages 15 to 20);
- Chronic Obstructive Pulmonary Disease or Asthma in Older Adults Admission Rate (Age 40 to 64 years) per 100,000 member months;
- Chronic Obstructive Pulmonary Disease or Asthma in Older Adults Admission Rate (Age 65 years and older) per 100,000 member months;
- Chronic Obstructive Pulmonary Disease or Asthma in Older Adults Admission Rate (Total Age 40+) per 100,000 member months;
- Statin Therapy for Patients With Diabetes: Statin Adherence 80%;
- Heart Failure Admission Rate (Age 18-64 years) per 100,000 member months;
- Heart Failure Admission Rate (Age 65+ years) per 100,000 member months;
- Heart Failure Admission Rate (Total Age 18+ years) per 100,000 member months;
- Adherence to Antipsychotic Medications for Individuals with Schizophrenia;
- Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose Testing (Age 12-17 years);
- Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose Testing (Total Age 1-17 years);
- Metabolic Monitoring for Children and Adolescents on Antipsychotics: Cholesterol Testing (Age 12-17 years);
- Metabolic Monitoring for Children and Adolescents on Antipsychotics: Cholesterol Testing (Total Age 1-17 years);
- Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose & Cholesterol Testing (Age 12-17 years); and
- Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose & Cholesterol Testing (Total Age 1-17 years).

Additional targeted opportunities for improvement are found in the MCO-specific HEDIS MY 2020 P4P Measure Matrix that follows.

P4P Measure Matrix Report Card 2021 (MY 2020)

The Pay-for-Performance (P4P) Matrix Report Card provides a comparative look at all measures in the Quality Performance Measures component of the “HealthChoices MCO Pay for Performance Program.” There are ten measures: seven are classified as both HEDIS and CMS Core Set measures, two are solely HEDIS and one is solely a CMS Child Core Set measure. The matrix:


1. Compares the Managed Care Organization’s (MCO’s) own P4P measure performance over the two most recent reporting years (2021 (MY 2020) and 2020 (MY 2019)); and
2. Compares the MCO’s MY 2020 P4P measure rates to the MY 2020 Medicaid Managed Care (MMC) Weighted Average, or the MCO Average as applicable.


A matrix represents the comparisons in each of **Figure 5.1** and **Figure 5.2**. In **Figure 5.1**, the horizontal comparison represents the MCO’s current performance as compared to the most recent MMC weighted average. When comparing a MCO’s rate to the MMC weighted average for each respective measure, the MCO rate can be either above average, average, or below average. For each rate, the MCO’s performance is determined using a 95% confidence interval for that rate. The difference between the MCO rate and MMC Weighted Average is statistically significant if the MMC Weighted Average is not included in the range, given by the 95% confidence interval. When noted, the MCO comparative differences represent statistically significant differences from the MMC weighted average.


The vertical comparison represents the MCO’s performance for each measure in relation to its prior year’s rates for the same measure. The MCO’s rate can trend up (↑), have no change, or trend down (↓). For these year-to-year comparisons, the statistical significance of the difference between two independent proportions was determined by calculating the z-ratio. A z-ratio is a statistical measure that quantifies the difference between two percentages when they come from two separate study populations. Noted comparative differences denote statistically significant differences between the years.


Figure 5.2 represents a matrix for the Plan All-Cause Readmissions measure. Instead of a percentage, performance on this measure is assessed via a ratio of observed readmissions to expected readmissions. Additionally, a MMC Weighted Average is not calculated. Given the different parameters for this measure, comparisons are made based on absolute differences in the O/E ratio between years and against the current year’s MCO Average.


For some measures, lower rates indicate better performance; these measures are specified in each matrix. Therefore, the matrix labels denote changes as above/better and below/worse. Each matrix is color-coded to indicate when a MCO’s performance for these P4P measures is notable or whether there is cause for action. Using the comparisons described above as applicable for each measure, the color codes are:

 The green box (A) indicates that performance is notable. The MCO’s MY 2020 rate is above/better than the MY 2020 average and above/better than the MCO’s MY 2019 rate.

 The light green boxes (B) indicate either that the MCO’s MY 2020 rate does not differ from the MY 2020 average and is above/better than MY 2019, or that the MCO’s MY 2020 rate is above/better than the MY 2020 average but there is no change from the MCO’s MY 2019 rate.

 The yellow boxes (C) indicate that the MCO’s MY 2020 rate is below/worse than the MY 2020 average and is above/better than the MY 2019 rate, or the MCO’s MY 2020 rate does not differ from the MY 2020 average and there is no change from MY 2019, or the MCO’s MY 2020 rate is above/better than the MY 2020 average but is lower/worse than the MCO’s MY 2019 rate. No action is required although MCOs should identify continued opportunities for improvement.

 The orange boxes (D) indicate either that the MCO’s MY 2020 rate is lower/worse than the MY 2020 average and there is no change from MY 2019, or that the MCO’s MY 2020 rate is not different than the MY 2020 average and is lower/worse than the MCO’s MY 2019 rate. **A root cause analysis and plan of action is therefore required.**

 The red box (F) indicates that the MCO’s MY 2020 rate is below/worse than the MY 2020 average and is below/worse than the MCO’s MY 2019 rate. **A root cause analysis and plan of action is therefore required.**



UHC Key Points

▪ A - Performance is notable. No action required. MCOs may have internal goals to improve.

Measure(s) that in MY 2020 are statistically significantly above/better than the MY 2020 MMC weighted average and statistically significantly above/better than the MCO's MY 2019 rate:

- Developmental Screening in the First Three Years of Life

▪ B - No action required. MCOs may identify continued opportunities for improvement.

Measure(s) that in MY 2020 are not statistically significantly different than the MY 2020 MMC weighted average but are statistically significantly above/better than the MCO's MY 2019 rate:

- Asthma Medication Ratio²

▪ C - No action required although MCOs should identify continued opportunities for improvement.

Measure(s) that in MY 2020 did not statistically significantly change from MY 2019, and are not statistically significantly different from the MY 2020 MMC weighted average:

- Controlling High Blood Pressure
- Postpartum Care
- Lead Screening in Children

▪ D - Root cause analysis and plan of action required.

Measure(s) that in MY 2020 are not statistically significantly different than the MY 2020 MMC weighted average, but are statistically significantly lower/worse than the MCO's MY 2019 rate:

- Comprehensive Diabetes Care: HbA1c Poor Control³
- Prenatal Care in the First Trimester
- Annual Dental Visit (Ages 2—20 years)

▪ F - Root cause analysis and plan of action required.

Measure(s) that in MY 2020 are statistically significantly lower/worse than MY 2019, and are statistically significantly lower/worse than the MY 2020 MMC weighted average:

- Well-Child Visits in the First 30 Months: First 15 Months of Life (6 or more visits)⁴

Measure(s) that in MY 2020 are lower/worse than the MY 2020 average and lower/worse than the MCO's MY 2019 rate:

- Plan All-Cause Readmissions⁵

² Asthma Medication Ratio was added as a P4P measure in 2021 (MY 2020) to replace Medication Management of Asthma.

³ Lower rates for Comprehensive Diabetes Care: HbA1c Poor Control indicate better performance.

⁴ Well-Child Visits in the First 30 Months: First 15 Months of Life (6 or more visits) replaces Well-Child Visits in the First 15 Months of Life, 6 or more.

⁵ Plan All-Cause Readmissions was added as a P4P measure in 2021 (MY 2020). Lower rates indicate better performance.

Figure 5.1: P4P Measure Matrix – Rate Measures

		Medicaid Managed Care Weighted Average Statistical Significance Comparison			
		Trend	Below/Worse than Average	Average	Above/Better than Average
Year to Year Statistical Significance Comparison	↑		C	B Asthma Medication Ratio ⁶	A Developmental Screening in the First Three Years of Life
	No Change		D	C Controlling High Blood Pressure Postpartum Care Lead Screening in Children	B
	↓		F Well-Child Visits in the First 30 Months: First 15 Months of Life (6 or more visits) ⁷	D Comprehensive Diabetes Care: HbA1c Poor Control ⁸ Prenatal Care in the First Trimester Annual Dental Visit (Ages 2—20 years)	C

Figure 5.2: P4P Measure Matrix – PCR Ratio Measure

		MCO Average Comparison			
		Trend	Below/Worse than Average	Average	Above/Better than Average
Year to Year	↓		F Plan All-Cause Readmissions ⁹	D	C

⁶ Asthma Medication Ratio was added as a P4P measure in 2021 (MY 2020) to replace Medication Management of Asthma.

⁷ Well-Child Visits in the First 30 Months: First 15 Months of Life (6 or more visits) replaces Well-Child Visits in the First 15 Months of Life, 6 or more.

⁸ Lower rates for Comprehensive Diabetes Care: HbA1c Poor Control indicate better performance.

⁹ Plan All-Cause Readmissions was added as a P4P measure in 2021 (MY 2020). Lower rates indicate better performance.

P4P performance measure rates for 2018 (MY 2017), 2019 (MY 2018), 2020 (MY 2019), and MY 2020 as applicable are displayed in **Table 5.1**. The following symbols indicate the differences between the reporting years.

- ▲ Statistically significantly higher than the prior year,
- ▼ Statistically significantly lower than the prior year or
- = No change from the prior year.

Table 5.1: P4P Measure Rates

Quality Performance Measure – HEDIS Percentage Rate Metric ¹	HEDIS 2018 (MY 2017) Rate	HEDIS 2019 (MY 2018) Rate	HEDIS 2020 (MY 2019) Rate	HEDIS MY 2020 Rate	HEDIS MY 2020 MMC WA
Comprehensive Diabetes Care - HbA1c Poor Control ²	37.1% =	35.1% =	30.6% =	37.5% ▲	38.4%
Controlling High Blood Pressure	65.7% =	65.2% =	69.1% =	62.8% =	63.4%
Prenatal Care in the First Trimester	84.4% =	84.9% =	93.2% ▲	89.3% ▼	88.9%
Postpartum Care	63.3% =	65.1% =	78.1% ▲	79.1% =	77.8%
Annual Dental Visits (Ages 2 – 20 years)	58.8% ▲	58.1% ▼	61.5% ▲	54.2% ▼	54.2%
Well-Child Visits in the First 30 Months: First 15 Months of Life (6 or more visits) ³	74.5% ▲	70.7% =	74.2% =	63.2% ▼	65.2%
Asthma Medication Ratio ⁴				62.4% ▲	64.8%
Lead Screening in Children			79.8% =	80.8% =	83.2%
Quality Performance Measure – Other Percentage Rate Metric	2018 (MY 2017) Rate	2019 (MY 2018) Rate	2020 (MY 2019) Rate	MY 2020 Rate	MY 2020 MMC WA
Developmental Screening in the First Three Years of Life (CMS Child Core)			59.5% ▲	60.8% ▲	59.6%
Quality Performance Measure – HEDIS Ratio Metric	HEDIS 2018 (MY 2017) Ratio	HEDIS 2019 (MY 2018) Ratio	HEDIS 2020 (MY 2019) Ratio	HEDIS MY 2020 Ratio	HEDIS MY 2020 MCO Average
Plan All-Cause Readmissions ⁵				1.13 ▲	1.02

¹ Statistically significant difference is indicated for all measures except Plan All-Cause Readmissions. For this measure, differences are indicated based on absolute differences in the O/E ratio between years.

² Lower rates for Comprehensive Diabetes Care: HbA1c Poor Control indicate better performance.

³ Well-Child Visits in the First 30 Months: First 15 Months of Life (6 or more visits) replaces Well-Child Visits in the First 15 Months of Life, 6 or more.

⁴ Asthma Medication Ratio was added as a P4P measure in 2021 (MY 2020) to replace Medication Management of Asthma.

⁵ Plan All-Cause Readmissions was added as a P4P measure in 2021 (MY 2020). Lower rates indicate better performance.

P4P: Pay-for-Performance; HEDIS: Healthcare Effectiveness Data and Information Set; MY: measurement year; MMC: Medicaid Managed Care; WA: weighted average.

Table 5.2: EQR Recommendations

Measure/Project	IPRO's Recommendation	Standards
Performance Improvement Projects (PIPs)		
Preventing Inappropriate Use or Overuse of Opioids	It was recommended that the MCO perform barrier or root cause analysis for ITMs with declining rates and consider revising those associated interventions or creating new interventions that may better impact the associated barrier.	Quality
	It was recommended that the MCO include a note in the Discussion section regarding which ITM outreaches, referrals, and follow-ups have been traditionally done via telehealth or telephonically compared to in-person follow ups. This would give an improved view of how COVID may be impacting these interventions.	Quality
Reducing Potentially Preventable Hospital Admissions, Readmissions and ED visits	It was recommended that the MCO include more modification in interventions for stagnating or worsening performance, especially in low provider outreach rates.	Quality
Performance Measures and CAHPS Survey		
Ambulatory Health Services	It is recommended that UHC improve access to ambulatory health services for its members. The measure Adults' Access to Preventive/Ambulatory Health Services was an opportunity in both 2020 and again in 2021 for ages 20-44 and 45-64 years old.	Access
Women's Health	It is recommended the MCO improve access to services related to women's health. The following measures were opportunities for improvement in 2020 and again in 2021: <ul style="list-style-type: none"> ○ Breast Cancer Screening; ○ Cervical Cancer Screening; and ○ Contraceptive Care for Postpartum Women: Most or moderately effective contraception - 60 days (Ages 15 to 20). 	Access
Services for Members on Antipsychotic Medication	It is recommended the MCO improve access to services for its members on antipsychotic medications. The following measures were opportunities for improvement in 2020 and again in 2021: <ul style="list-style-type: none"> ○ Adherence to Antipsychotic Medications for Individuals with Schizophrenia; ○ Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose Testing (Ages 12-17 years; 1-17 years); ○ Metabolic Monitoring for Children and Adolescents on Antipsychotics: Cholesterol Testing (Ages 12-17 years; 1-17 years); and ○ Metabolic Monitoring for Children and Adolescents on Antipsychotics: Blood Glucose & Cholesterol Testing (Ages 12-17 years; 1-17 years). 	Access
Satisfaction with Health Plan and Health Care	It is recommended that UHC focus on improving health plan and health care satisfaction for its members who are children. The following items from the MY 2020 CAHPS survey both fell below the MMC weighted average and fell from 2020: <ul style="list-style-type: none"> ○ Satisfaction with Child's Health Plan (Rating of 8–10); ○ Information or Help from Customer Service (Usually or Always); ○ Satisfaction with Health Care (Rating of 8–10); and ○ Appointment for Routine Care When Needed (Usually or Always). 	Quality, Timeliness

VI: Summary of Activities

Performance Improvement Projects

- As previously noted, UHC's Opioid and Readmission PIP proposal submissions were validated. The MCO received feedback and subsequent information related to these activities from IPRO.

Performance Measures

- UHC reported all HEDIS, PA-Specific, and CAHPS Survey performance measures in 2021 for which the MCO had a sufficient denominator.

Structure and Operations Standards

- UHC was found to be fully compliant on all contract and with state and federal managed care regulations reviewed. Compliance review findings for UHC from RY 2021, RY 2020, and RY 2019 were used to make the determinations.

2020 Opportunities for Improvement MCO Response

- UHC provided a response to the opportunities for improvement issued in the 2020 annual technical report and a root cause analysis and action plan for those measures on the HEDIS 2020 P4P Measure Matrix receiving either "D" or "F" ratings.

2021 Strengths and Opportunities for Improvement

- Both strengths and opportunities for improvement have been noted for UHC in 2021. A response will be required by the MCO for the noted opportunities for improvement in 2022.

Appendix

Performance Improvement Project Interventions

As referenced in **Section I: Validation of Performance Improvement Projects, Table A.1.1** lists all of the interventions outlined in the MCO’s most recent PIP submission for the review year.

Table A.1.1: PIP Interventions

Summary of Interventions
UnitedHealthcare of Pennsylvania (UHC) – Opioid
<p>1. Behavioral Health Advocates Behavioral Health Advocates (BHA) outreach to members with an OUD diagnosis in acute care to connect them to MAT providers</p>
<p>2. Warm Handoff to Center of Excellence (COE) BHAs coordinate warm handoffs to Centers of Excellence for members with an OUD related ED visit. A warm handoff is considered a transfer of care between two members of the health care team with the member present. The warm handoff is usually completed face to face but may be completed as a conference call between all the parties if barriers prevent a face-to-face transfer of care (i.e., Covid-19).</p>
<p>3. Optum Pharmacy Retrospective Abused Medication Program (RAMP) This is a provider-targeted program designed to minimize the occurrence of drug abuse, diversion, and inappropriate use in members utilizing high-risk medications. Medication classes include Opioids. Benzodiazepines; Buprenorphine. Provider outreach and education is completed if member is identified to be on a high cumulative daily dose of opioid analgesic and/or overlap of an opioid analgesic and benzodiazepine.</p>
<p>4. ACO/PCMH Pilot on Opioid Performance Indicators Key Performance indicators for opioid prescribing practices will be shared with each ACO/PCMH during JOC committee meetings.</p>
<p>5. Value Based Purchasing Program SUD specific New VBP program was established with Temple University focusing on medication adherence to MAT. This program may expand to additional providers over the course of the PIP.</p>
<p>6. Siloam Program - provides alternative therapy and wellness services to members with HIV, SUD, diabetes, and chronic pain in select Philadelphia zip codes. Program offering yoga, reiki, and wellness counseling, among other alternative therapies.</p>
<p>7. SUD Pregnancy Programs Expansion SUD Substance Use Disorder Maternal Health Homes – SUD Health homes are OB providers that work with women with a SUD diagnoses throughout prenatal and into postpartum care to ensure consistent care is available, support is in place, and medications are managed. These supports continue into postpartum timeframe to ensure a more stable and healthy development of family. Pregnant women enrolled in SUD Maternal Health Homes are more likely to be engaged in MAT and less likely to discontinue treatment early. In 2019, 89% of members enrolled in a Substance Use Disorder Maternal Health Home received MAT, and 50% of those members had 365 days of continuous treatment in 2019. All members enrolled in 2019 had continuous MAT from the date of program enrollment until the end of the calendar year. As a result, this program was expanded in January 2020 and two additional SUD maternal health homes were added.</p>

Summary of Interventions

UnitedHealthcare of Pennsylvania (UHC) – Readmission

1. Accountable Care Organization Program Expansion

Expansion of ACO Program in 2020 to include a larger percentage of the overall member population. Goal of the ACO program is to reduce avoidable ED visits and admits by near real-time data sharing, population management tools, and same day appointments. This is a strategic program to partner with the Practitioner sites whose staff will review discharges daily in UHC's Accountable Care Population Registry and outreach to their recently discharged members to schedule PCP visits within 7 days. This can assist with reducing avoidable emergency department visits, admissions & readmissions.

2. PCMH Program Expansion

Expansion of the PCMH Program in 2020 to include a larger percentage of the overall member population. The PCMH program focuses on coordination of care in a community-based model. Goals of the PCMH program are a reduction in preventable ED visits and admits by Providing comprehensive primary care for children, youth, and adult, facilitating partnerships between patients and their personal physician, the patient's family and caregivers, and the community, Promote increased access to care and improved care quality, Incorporate surveys in practices related to gaining information on social determinants of health (SDoH).

3. Verification of Provider Visits (VOPV)

Outreach call is completed to Primary Care Provider by WPC team within 7 days of hospital discharge to assure PCP is aware of hospitalization and member has a follow up appointment.

4. DocChat

DocChat is an application-based intervention that allows members to text with an Emergency Physician to assist in determining a correct level of care. The target population for the resource is members who have two or more Emergency room visits specifically for low acuity non-emergent diagnoses receive mailer, email, or text message to introduce the program, but it is accessible to all members.

5. Urgent Care Mailer Expansion

Members who utilize the ED three or more times in 6 months in Med Express counties currently receive a mailer with information on Med Express locations available in their area. This program will be expanded and members outside of those counties will receive a mailer with education appropriate ER utilization and a list of in-network urgent care centers in their area.

Process for mailer creation and approval took longer than expected. Mailings began Q2 2021. No mailings completed in 2020.

6. Lancaster EMS (LEMSA)

Partnership with LEMSA to provide Paramedicine services in Lancaster county. In home paramedicine will be provided to members coming out of an inpatient stay who are high risk for readmission. These members may have diagnoses including but not limited to CHF, COPD, Sepsis, DM, other chronic dx. Visits include medication reconciliation, follow up care coordination, medical services as needed, and general safety and wellness education.

7. AdhereHealth™ SPC/SPD Project

AdhereHealth™ vendor is being contracted to complete outreach to members with cardiovascular disease and/or diabetes who are noncompliant with their Statin medication. AdhereHealth™ performs telephonic outreach to the member to identify and address barriers related to medication adherence and provide member education when feasible.

Summary of Interventions

Program launched in September 2020 for SPC. SPD outreach began in October 2020.

8. Pennsylvania Pharmacist Care Network (PPCN) Program

Members with COPD and/or Diabetes receive education on their disease state and medication from a PPCN pharmacist. In person education is provided to the member where they currently fill their prescriptions.

Program was planned to launch in Q4 2020 but did not launch until Q2 2021 due to delays in contracting process.

9. ICP Joint Operating Committee (JOC) Meetings

JOC Meetings were started with the BHMCOs in Q4 2020. The JOC meetings are in addition to the clinical rounds that currently take place with the BHMCOs. These JOC meetings will include BHMCO medical directors and focus on ways to improve integration of care and coordination of care with BHMCOs.

In Q4 2020 the WPC team began to share gap in care lists for the SAA measure with the BHMCOs to allow for better collaboration on these members and referral to the ICP program if needed. This modification was made due to ITM 10 not being implemented as planned.

10. AdhereHealth™ SAA Project

AdhereHealth™ vendor is being contracted to complete outreach to the SAA measure population who are noncompliant with their antipsychotic medication. AdhereHealth™ performs telephonic outreach to the member and the prescriber to identify and address barriers related to medication adherence and provide member education when feasible.

This intervention did not launch in 2020 as planned due to barriers encountered in the contracting process. The vendor declined to move forward with outreach. As a result, sharing of gap in care lists for the SAA measure with the BHMCOs was implemented under ITM 9 BHMCO JOC meetings to further address this barrier

11. Disparities Score Card

UHC has developed a disparity score card to assure that providers are aware of the disparities that currently exist in the African American member population. The Clinical Practice Consultants (CPCs) review this score card with individual practices. The score card includes the individual practice rates and benchmarking comparison to peers. This not only educates practices on their individual rates for the targeted measures, but also provides a platform for discussion and education on how to improve healthcare disparities at the practice level

12. African American Blood Pressure and Diabetes Pilot Project

African American members with gaps in care for poorly controlled diabetes and high blood pressure, which puts them at higher risk for inpatient admission, readmission, and ED utilization. Members receive a culturally appropriate mailer followed by a live telephonic outreach call by a QM team member to support screening education, appointment scheduling, Bio-IQ in-home test kit, and a home visit (where applicable). When calling members, we review all risk factors and program incentives, and members may qualify for 2020 reward program for completing a HbA1c test. A resource listing of program and services was created and shared during live calls with members. Members engaged will be monitored over 90 days and claims reviewed to determine if additional outreach is needed

PIP: performance improvement project.